USRE31617E - Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones - Google Patents

Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones Download PDF

Info

Publication number
USRE31617E
USRE31617E US06/421,501 US42150182A USRE31617E US RE31617 E USRE31617 E US RE31617E US 42150182 A US42150182 A US 42150182A US RE31617 E USRE31617 E US RE31617E
Authority
US
United States
Prior art keywords
sub
compound
calc
anal
found
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/421,501
Inventor
Warren N. Beverung, Jr.
Richard A. Partyka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/521,306 external-priority patent/US3932407A/en
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Priority to US06/421,501 priority Critical patent/USRE31617E/en
Application granted granted Critical
Publication of USRE31617E publication Critical patent/USRE31617E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/12—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/19—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Definitions

  • the compounds of the present invention are useful in the control of mild to severe hypertension, as anti-clotting agents and bronchodilators.
  • R 1 is H, phenyl or (lower)alkyl
  • R 2 and R 3 when alike are H, chloro, bromo, fluoro, (lower)alkyl, hydroxy or (lower)alkoxy
  • R 2 and R 3 when different are hydrogen, chloro, bromo, fluoro, SO 3 H, CF 3 , hydroxy, nitro, amino, phenyl or (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together
  • R 2 and R 3 are methylenedioxy or the residue of a phenyl ring
  • n is an integer of 1 or 2; or a pharmaceutically acceptable acid addition salt thereof are hypotensive, blood platelet antiaggregative and/or bronchodilator agents.
  • This invention relates to new synthetic compounds of value as hypotensive and blood platelet antiaggregative agents.
  • the compounds of the invention are 1,2,3,5-tetrahydroimidazo-[2,1-b]-quinazolin-2-ones having the formula ##STR9## or 6-[H]-1,2,3,4-tetrahydropyrimido-[2,1-b]-quinazolin-2-ones having the formula ##STR10## in which R 1 is H, phenyl or (lower)alkyl, R 2 and R 3 when alike are H, chloro, bromo, fluoro, hydroxy or (lower)alkyl of 1 to 3 carbons or (lower)alkoxy of 1 to 3 carbon atoms, R 2 and R 3 when different are hydrogen, chloro, bromo, fluoro, CF 3 , SO 3 H, (lower)-alkyl, hydroxy, nitro, amino, (lower)alkoxy or phenyl, or when taken together R
  • Hypertension is a rather common and serious disease, particularly in elderly people. High blood pressure, a result of hypertension, is a common but serious disease. Most particularly, hypertension is often the cause of crippling or fatal strokes in the elderly. It was therefore an object of the present invention to provide compounds useful in the treatment of mild to severe hypertension.
  • the compounds of the present invention are represented as having the formulas Ia and Ib.
  • compounds Ia and Ib can exist in several possible tautomeric forms, e.g.: ##STR12##
  • optical isomers of those compounds having an asymetric center e.g., (+) and (-)-5,6-dimethyl-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one.
  • the racemic mixture of these compounds are resolved by those methods commonly known in the art.
  • nontoxic salts that are pharmaceutically acceptable include the hydrochlorides, hydrobromides, hydroiodides, (lower)alkylsulfates, (lower)-alkyl and aryl sulfonates, phosphates, sulfates, maleates, fumarates, succinates, tartrates, citrates, and other commonly used in the art.
  • the salts obtained through the variation of the acid used in some cases have special advantage due to increased stability, increased solubility, decreased solubility, ease of crystallization, lack of objectionable taste, etc., but these are all subsidiary to the main physiological action of the free base, which is independent of the character of the acid used in the preparation of the salt.
  • R 2 or R 3 is a bromine or NO 2
  • R 1 is H, phenyl or (lower)alkyl
  • R 2 and R 3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy or (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms
  • R 2 and R 3 when different are hydrogen, chloro, bromo, fluoro, CF 3 , SO 3 H, hydroxy, nitro, amino, phenyl or (lower)alkyl or (lower)alkoxy or when taken together
  • R 2 and R 3 are methylenedioxy or the residue of a phenyl ring
  • n is an integer of 1 or 2; which process comprises the consecutive steps of
  • the pharmaceutically acceptable, nontoxic salts of compound I are readily prepared by the addition of stoichiometric (or larger quantities) of the desired acid to a solution of compound I. Since compound I has only one strongly basic grouping, it only forms monosalts, e.g., monohydrochloride.
  • a preferred embodiment of the present invention is the compound having the formula ##STR17## in which R 1 is H, phenyl or (lower)alkyl, R 2 and R 3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkoxy of 1 to 3 carbon atoms or (lower)alkyl of 1 to 3 carbon atoms, R 2 and R 3 when different are hydrogen, chloro, bromo, fluoro, CF 3 , SO 3 H, hydroxy, phenyl, amino, nitro, (lower)alkyl or (lower)alkoxy or when taken together R 2 and R 3 are methylenedioxy or the residue of a phenyl ring (--C ⁇ CH--CH ⁇ CH--), and n is an integer of 1 or 2; or a pharmaceutically acceptable acid addition salt thereof.
  • a more preferred embodiment is the compound having the formula ##STR18## in which R 1 is H, phenyl or (lower)alkyl, R 2 and R 3 when different are hydrogen, chloro, bromo, cluoro, CF 3 , SO 3 H, (lower)alkyl or (lower)alkoxy, hydroxy, nitro, amino, or phenyl, R 2 and R 3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R 2 and R 3 are methylenedioxy or the residue of a phenyl ring (--CH ⁇ CH--CH ⁇ CH--), and n is an integer of 1 or 2; or a pharmaceutically acceptable acid addition salt thereof.
  • a more preferred embodiment is the compound having the formula ##STR19##
  • R 1 is H, phenyl or (lower)alkyl
  • R 2 and R 3 when different are hydrogen, chloro, bromo, fluoro, CF 3 , SO 3 H, hydroxy, (lower)alkyl or (lower)alkoxy, nitro, amino or phenyl
  • R 2 and R 3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R 2 and R 3 are methylenedioxy or the residue of a phenyl ring (--CH ⁇ CH--CH ⁇ CH--); or a pharmaceutically acceptable acid addition salt thereof.
  • a still more preferred embodiment is the compound having the formula ##STR20## in which R 2 and R 3 when differnt are hydrogen, CF 3 , SO 3 H, chloro, bromo, fluoro, nitro, amino, hydroxy, (lower)alkoxy or (lower)alkyl, R 2 and R 3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R 2 and R 3 are methylenedioxy or the residue of a phenyl ring (--CH ⁇ CH--CH ⁇ CH--); or a pharmaceutically acceptable acid addition salt thereof.
  • a most preferred embodiment is the compound having the formula ##STR21## in which R 2 and R 3 are alike or different and are H, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, chloro or fluoro; or a pharmaceutically acceptable salt thereof.
  • R 2 and R 3 are alike or different and are H, Cl, methoxy, methyl, nitro or hydroxy and R 1 is H, phenyl or methyl; or the hydrochloride salt thereof.
  • R 1 , R 2 and R 3 are H;
  • R 2 and R 3 are methoxy and R 1 is H;
  • R 1 and R 2 are H and R 3 is methoxy
  • R 2 is methoxy and R 1 and R 3 are H;
  • R 1 and R 2 are H and R 3 is methyl
  • R 2 is methyl and R 1 and R 3 are H;
  • R 2 and R 3 are methyl and R 1 is H;
  • R 2 and R 3 taken together are --CH ⁇ CH--CH ⁇ CH-- and R 1 is H;
  • R 2 is NO 2 , R 3 is methyl and R 1 is H; or the hydrochloride salts thereof;
  • R 2 is chloro, R 3 is methyl and R 1 is H; or the hydrochloride salt thereof;
  • R 1 and R 3 are CH 3 and R 2 is H; or the hydrochloride salt thereof.
  • (lower)alkyl shall mean straight and branched chain saturated aliphatic groups having 1 to 6 carbons inclusive unless otherwise stated.
  • the term (lower)alkanol or (lower)alkoxy shall have the same connotation, an alcohol or alkoxy group of 1 to 6 carbons inclusive unless otherwise stated.
  • the blood pressure of unanesthetized rats and dogs was measured directly by means of a transducer attached to an intra-arterial cannula and in anesthetized dogs by a mercury manometer attached to a carotid cannula.
  • the compounds of the instant invention were tested as the hydrochloride salts by the above method in genetically hypertensive rats in doses of 50 mg./kg. orally.
  • the compounds of the present invention are administered orally and/or parenterally, in accordance with conventional procedures for the administration of hypotensive agents in an amount of from about 0.5 mg./kg./dose to 30 mg./kg./dose depending upon the route of administration and the particular compound of the invention.
  • the preferred dosage for the compounds of the invention is in the range of about 1.0 to 15.0 mg./kg./dose two to four times a day.
  • the aggregometer method of Born (1), as modified by Mustard et al. (2) was used to assess the in vitro activity of the various compounds as to inhibition of adenosine diphosphate (ADP) and collagen induced platelet aggregation.
  • Platelet rich plasma was separated by centrifugation from citrated (3.8 percent) rabbit blood.
  • ADP in final concentration of 0.5 mcg./ml. or 0.05 ml. of a collagen suspension prepared according to the method described by Evans et al. (3) was used to induce aggregation.
  • the various compounds tested were dissolved in dimethylsulfoxide (DMSO) so that 5 mcl. added to the platelet rich plasma would yield the desired test concentration.
  • Vehicle control trials were done and compared with aggregation induced in platelet rich plasma containing various concentrations of the test compounds. Dose response curves were obtained and Effective Concentration (EC50) values calculated.
  • DMSO dimethylsulfoxide
  • Table I is illustrative of the hypotensive and blood platelet anti-aggregative activity of some of the preferred embodiments of the present invention.
  • blood samples are taken.
  • the blood is centrifuged to obtain the blood platelet-rich plasma. Aggregation of this plasma is induced with ADP or collagen. This is the control.
  • the animals are then dosed with the compounds to be tested (orally or parenterally). Depending upon the route of administration, 1 to 2 hours are allowed to elapse after dosing. Blood is drawn and the same procedure employed as for the control in untreated animals.
  • the dose required to produce 50% inhibition of the aggregation is determined by dose response data obtained in this manner.
  • o-Nitrobenzylamine hydrochloride (20.4 g., 0.114 mole) was dissolved in a minimum volume of water and the solution was made strongly basic by addition of 10% sodium hydroxide. The clear oil which formed was extracted into two 120-ml. portions of ether. The ether was dried with 10 g. of anhydrous sodium sulfate, filtered, and finally dried over Drierite. The dried solution was filtered and evaporated, leaving a yellow oil. The oil was dissolved in 100 ml. of absolute ethanol and 11.4 g (0.114 mole) of freshly distilled ethyl acrylate was added. This solution was allowed to stand overnight and the solvent removed by distillation from a steam-cone.
  • the aqueous solution was made basic (pH 8) by the dropwise addition of 40% sodium hydroxide, the basic solution stirred for 30 minutes and the precipitate filtered under suction.
  • the yellow solid was washed with water, then acetone and dried under high vacuum (almost quantitative yield).
  • the solid was suspended in water (350 ml.), the solution saturated with hydrogen chloride, heated to boiling and filtered. Saturated sodium chloride solution (100 ml.) was added, the mixture cooled and the precipitate isolated yielding 6.92 g. (43% yield) of a yellow powder.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Optionally substituted 1,2,3,5-tetrahydroimidazol[2,1-b]-quinazolin-2-ones and 6-[H]-1,2,3,4-tetrahydropyrimidol[2,1-b]quinazolin-2-ones or the pharmaceutically acceptable salts thereof are compounds useful as blood platelet anti-aggregative and/or antihypertensive and/or bronchodilator agents in mammals, including humans.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of co-pending application Ser. No. 416,891, filed Nov. 19, 1973 now abandoned, which is a continuaton-in-part of Ser. No. 396,638, filed Sept. 12, 1973 now abandoned, which is a continuation-in-part of Ser. No. 291,450, filed Sept. 22, 1972 now abandoned, which in turn was a continuation-in-part of application Ser. No. 223,723, filed Feb. 4, 1972 now abandoned.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The compounds of the present invention are useful in the control of mild to severe hypertension, as anti-clotting agents and bronchodilators.
2. Description of the Prior Art
The compounds of the present invention are new and novel. The literature discloses the following prior art:
A. The compounds characterized as 1- and 9-alkyl-2,3-dihydroimidazo-[1,2-a]-benzimidazoles [R. J. North and A. R. Day, J. Hetero. Chem., 655 (1969)]. The compounds have the following structure: ##STR1## in which R1 and R2 are optionally substituted with alkyl functions.
B. B. Loev, T. Jen and R. A. McLean, Experientia, 27, 875 (1971) disclose the compound having the formula ##STR2## as having potent antihypertensive activity in rats, dogs, cats and rabbits.
C. R. Grout and M. Partridge, J. Chem. Soc., 3551 (1960) report the synthesis of the compound ##STR3## No antihypertensive activity was reported.
D. K. Lempert and G. Doleschall, Experientia, 18, 401 (1962) and Acta Chimica Academiae Scientiarum Hungaricae, 45, 357-68 (1965) report the synthesis of the compounds ##STR4##
No antihypertensive activity was reported.
E. A. Simonov et al., Khim. Farmatseut, Zh., (1969) [Annual Reports in Medicinal Chemistry, Chapt. 6, 53 (1969)] report the preparation of 9-substituted imidazobenzimidazoles having the formula ##STR5## said compounds reported to have hypotensive effects in animals but no detailed data was presented.
F. G. E. Hardtmann, German Patent No. 2,025,248 (1970) reports bronchodilating the hypotensive effects for the compounds having the formula ##STR6##
G. T. Jen et al., J. Med. Chem., 15 (7), 727-31 (1972) describe the compounds having the formula ##STR7## in which R is H, 6-Cl, 7-Cl, 7-MeO, 7-OH, 8-Cl, 9-Cl and 9-CH3 as being hypotensive agents.
SUMMARY OF THE INVENTION
The compounds having the formula ##STR8## in which R1 is H, phenyl or (lower)alkyl, R2 and R3 when alike are H, chloro, bromo, fluoro, (lower)alkyl, hydroxy or (lower)alkoxy, R2 and R3 when different are hydrogen, chloro, bromo, fluoro, SO3 H, CF3, hydroxy, nitro, amino, phenyl or (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R2 and R3 are methylenedioxy or the residue of a phenyl ring, and n is an integer of 1 or 2; or a pharmaceutically acceptable acid addition salt thereof are hypotensive, blood platelet antiaggregative and/or bronchodilator agents.
DETAILED DESCRIPTON
This invention relates to new synthetic compounds of value as hypotensive and blood platelet antiaggregative agents. Most particularly the compounds of the invention are 1,2,3,5-tetrahydroimidazo-[2,1-b]-quinazolin-2-ones having the formula ##STR9## or 6-[H]-1,2,3,4-tetrahydropyrimido-[2,1-b]-quinazolin-2-ones having the formula ##STR10## in which R1 is H, phenyl or (lower)alkyl, R2 and R3 when alike are H, chloro, bromo, fluoro, hydroxy or (lower)alkyl of 1 to 3 carbons or (lower)alkoxy of 1 to 3 carbon atoms, R2 and R3 when different are hydrogen, chloro, bromo, fluoro, CF3, SO3 H, (lower)-alkyl, hydroxy, nitro, amino, (lower)alkoxy or phenyl, or when taken together R2 and R3 are methylenedioxy or the residue of a phenyl ring; or a pharmaceutically acceptable acid addition salt thereof.
Hypertension is a rather common and serious disease, particularly in elderly people. High blood pressure, a result of hypertension, is a common but serious disease. Most particularly, hypertension is often the cause of crippling or fatal strokes in the elderly. It was therefore an object of the present invention to provide compounds useful in the treatment of mild to severe hypertension.
Subsequent to the preparation of some of the compounds of the present invention, it was found that most of the compounds also possessed unique properties as blood platelet anti-aggregative agents. These compounds are useful in the prevention of intravascular thrombosis, prevention of coronary thrombosis, prevention of transient ischemic episodes, prevention of platelet thrombosis in the use of prosthetic devises (artificial heart valves, etc.). A large number of the compounds of the present invention have also been found to possess desirable bronchodilator activity in mammals.
The objects of the present invention have been achieved by the provision of the compound having the formula ##STR11## in which R1, R2 and R3 are as defined above.
For the purpose of this disclosure, the compounds of the present invention are represented as having the formulas Ia and Ib. However, compounds Ia and Ib can exist in several possible tautomeric forms, e.g.: ##STR12##
All the possible tautomers are considered an integral part of the present invention and all these forms are considered included when the compounds are represented as formula Ia or Ib.
Also considered an integral part of this invention are the optical isomers of those compounds having an asymetric center, e.g., (+) and (-)-5,6-dimethyl-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one. The racemic mixture of these compounds are resolved by those methods commonly known in the art.
The nontoxic salts that are pharmaceutically acceptable include the hydrochlorides, hydrobromides, hydroiodides, (lower)alkylsulfates, (lower)-alkyl and aryl sulfonates, phosphates, sulfates, maleates, fumarates, succinates, tartrates, citrates, and other commonly used in the art.
The salts obtained through the variation of the acid used in some cases have special advantage due to increased stability, increased solubility, decreased solubility, ease of crystallization, lack of objectionable taste, etc., but these are all subsidiary to the main physiological action of the free base, which is independent of the character of the acid used in the preparation of the salt.
Most of the compounds of the present invention can be prepared as shown in Chart I. ##STR13## R1, R2 and R3 and n are as defined above and R4 is (lower)alkyl.
In other cases, particularly when R2 or R3 is a bromine or NO2, it may be desirable to brominate or nitrate after producing compound I (see examples).
Two alternative processes for the preparation of the compounds of the instant invention are found in Charts II and III. In some instances, these are the preferred synthetic route. ##STR14##
Compounds possessing a substituent at positions 5 and 6 are preferably prepared by the synthetic route illustrated by Chart II.
The objectives of the present invention have been achieved by the provision according to the present invention, of the process for the synthesis of compounds having the formula ##STR15## in which R1 is H, phenyl or (lower)alkyl, R2 and R3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy or (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, R2 and R3 when different are hydrogen, chloro, bromo, fluoro, CF3, SO3 H, hydroxy, nitro, amino, phenyl or (lower)alkyl or (lower)alkoxy or when taken together R2 and R3 are methylenedioxy or the residue of a phenyl ring, and n is an integer of 1 or 2; which process comprises the consecutive steps of
1. reducing one mole of compound III, preferably with a noble metal catalyst, particularly 5% palladium on carbon, in the presence of hydrogen under positive pressure until three moles of hydrogen are absorbed, in an organic solvent, preferably a (lower)alkanol such as ethanol, n-propanol, isopropanol and the like to produce a compound having the formula ##STR16## in which R1, R2, R3, R4 are n are as defined above; and 2. treating one mole of compound IV with at least one mole of cyanogen bromide, but preferably about 1.0 to 2.0 moles, and most preferably about 1.0 to 1.1 moles, in a reaction inert organic solvent, i.e., a (lower)alkanol, preferably ethanol, n-propanol, isopropanol, with or without the presence of some water, with the aid of heat, preferably at about reflux temperatures, to produce compound I.
The pharmaceutically acceptable, nontoxic salts of compound I are readily prepared by the addition of stoichiometric (or larger quantities) of the desired acid to a solution of compound I. Since compound I has only one strongly basic grouping, it only forms monosalts, e.g., monohydrochloride.
A preferred embodiment of the present invention is the compound having the formula ##STR17## in which R1 is H, phenyl or (lower)alkyl, R2 and R3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkoxy of 1 to 3 carbon atoms or (lower)alkyl of 1 to 3 carbon atoms, R2 and R3 when different are hydrogen, chloro, bromo, fluoro, CF3, SO3 H, hydroxy, phenyl, amino, nitro, (lower)alkyl or (lower)alkoxy or when taken together R2 and R3 are methylenedioxy or the residue of a phenyl ring (--C═CH--CH═CH--), and n is an integer of 1 or 2; or a pharmaceutically acceptable acid addition salt thereof.
A more preferred embodiment is the compound having the formula ##STR18## in which R1 is H, phenyl or (lower)alkyl, R2 and R3 when different are hydrogen, chloro, bromo, cluoro, CF3, SO3 H, (lower)alkyl or (lower)alkoxy, hydroxy, nitro, amino, or phenyl, R2 and R3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R2 and R3 are methylenedioxy or the residue of a phenyl ring (--CH═CH--CH═CH--), and n is an integer of 1 or 2; or a pharmaceutically acceptable acid addition salt thereof.
A more preferred embodiment is the compound having the formula ##STR19##
in which R1 is H, phenyl or (lower)alkyl, R2 and R3 when different are hydrogen, chloro, bromo, fluoro, CF3, SO3 H, hydroxy, (lower)alkyl or (lower)alkoxy, nitro, amino or phenyl, R2 and R3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R2 and R3 are methylenedioxy or the residue of a phenyl ring (--CH═CH--CH═CH--); or a pharmaceutically acceptable acid addition salt thereof.
A still more preferred embodiment is the compound having the formula ##STR20## in which R2 and R3 when differnt are hydrogen, CF3, SO3 H, chloro, bromo, fluoro, nitro, amino, hydroxy, (lower)alkoxy or (lower)alkyl, R2 and R3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R2 and R3 are methylenedioxy or the residue of a phenyl ring (--CH═CH--CH═CH--); or a pharmaceutically acceptable acid addition salt thereof.
A most preferred embodiment is the compound having the formula ##STR21## in which R2 and R3 are alike or different and are H, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, chloro or fluoro; or a pharmaceutically acceptable salt thereof.
Another more preferred embodiment is the compound having the formula ##STR22## in which R2 and R3 are alike or different and are H, Cl, methoxy, methyl, nitro or hydroxy and R1 is H, phenyl or methyl; or the hydrochloride salt thereof.
The most preferred embodiments are the compounds of formula IM in which
1. R1, R2 and R3 are H;
2. R2 and R3 are methoxy and R1 is H;
3. R1 and R2 are H and R3 is methoxy;
4. R2 is methoxy and R1 and R3 are H;
5. R1 and R2 are H and R3 is methyl;
6. R2 is methyl and R1 and R3 are H;
7. R2 and R3 are methyl and R1 is H;
8. R2 and R3 taken together are --CH═CH--CH═CH-- and R1 is H;
9. R2 is NO2, R3 is methyl and R1 is H; or the hydrochloride salts thereof;
10. R2 is chloro, R3 is methyl and R1 is H; or the hydrochloride salt thereof;
11. R1 and R3 are CH3 and R2 is H; or the hydrochloride salt thereof.
For the purpose of this disclosure, the term (lower)alkyl shall mean straight and branched chain saturated aliphatic groups having 1 to 6 carbons inclusive unless otherwise stated. The term (lower)alkanol or (lower)alkoxy shall have the same connotation, an alcohol or alkoxy group of 1 to 6 carbons inclusive unless otherwise stated.
Pharmacological evaluation has indicated the compounds of the present invention possess hypotensive activity.
The blood pressure of unanesthetized rats and dogs was measured directly by means of a transducer attached to an intra-arterial cannula and in anesthetized dogs by a mercury manometer attached to a carotid cannula.
The compounds of the instant invention were tested as the hydrochloride salts by the above method in genetically hypertensive rats in doses of 50 mg./kg. orally.
At the present time, indications are that the compounds do not appear to be acting in the same way as 2-(2,6-dichloroanilino)-2-imidazoline hydrochloride ["CATAPRES"]. Their activity is probably not attributable to α-adrenergic blockade or to ganglionic blocking action.
In the treatment of hypertension in animals including man, the compounds of the present invention are administered orally and/or parenterally, in accordance with conventional procedures for the administration of hypotensive agents in an amount of from about 0.5 mg./kg./dose to 30 mg./kg./dose depending upon the route of administration and the particular compound of the invention. The preferred dosage for the compounds of the invention is in the range of about 1.0 to 15.0 mg./kg./dose two to four times a day.
Pharmacological evaluation has also indicated the compounds of the present invention possess blood platelet anti-aggregative activity.
The aggregometer method of Born (1), as modified by Mustard et al. (2) was used to assess the in vitro activity of the various compounds as to inhibition of adenosine diphosphate (ADP) and collagen induced platelet aggregation. Platelet rich plasma was separated by centrifugation from citrated (3.8 percent) rabbit blood. ADP in final concentration of 0.5 mcg./ml. or 0.05 ml. of a collagen suspension prepared according to the method described by Evans et al. (3) was used to induce aggregation. The various compounds tested were dissolved in dimethylsulfoxide (DMSO) so that 5 mcl. added to the platelet rich plasma would yield the desired test concentration. Vehicle control trials were done and compared with aggregation induced in platelet rich plasma containing various concentrations of the test compounds. Dose response curves were obtained and Effective Concentration (EC50) values calculated.
1. Born, G. V. R., J. Physiol., London, 162, 67P (1962).
2. Mustard, J. F., Hegardt, B. Rowsell, H. C. and MacMillan, R. L., J. Lab. Clin. Med. 64, 548 (1964).
3. Evans, G. Marian M. C., Packham, M. A., Nishizawa, E. E., Mustard, J. F. and Murphy, E. A., J. Exp. Med., 128, 877 (1968).
Table I is illustrative of the hypotensive and blood platelet anti-aggregative activity of some of the preferred embodiments of the present invention.
                                  TABLE I                                 
__________________________________________________________________________
 ##STR23##                                                                
                                         In Vivo/In Vitro*                
Com-                                                                      
    R                   Blood Pressure                                    
                                In Vitro Rabbits I.P.                     
                                                 Dogs P.O.                
pound                                                                     
    Position            % Change Rats                                     
                                EC.sub.50 (mcg/ml.)                       
                                         ED.sub.50 (mg./kg.)              
                                                 5 mg./kg. ADP            
No. 6       7   8   9   P.O. 50 mg./kg.                                   
                                ADP Collagen                              
                                         ADP     % Inhibition             
__________________________________________________________________________
1   H       H   H   H   -36 ± 6                                        
                                6   2    >72                              
2   Cl      H   H   H   -37 ± 8                                        
                                1   0.02 2                                
3   H       Cl  H   H   -4 ± 5                                         
                                0.5 0.2  >10                              
4   H       H   Cl  H   -14     6   1.5  18                               
5   H       H   H   Cl  -10 ± 1                                        
                                7   0.3  6                                
6   H       Br  H   H   -8 ± 3                                         
                                0.4 0.2  5                                
7   H       H   F   H   -27 ± 3                                        
                                6   2    >10                              
8   H       NO.sub.2                                                      
                H   H   5 ± 2                                          
                                2   0.2  >10                              
9   H       NH.sub.2                                                      
                H   H   -10 ± 14                                       
                                50  6                                     
10  CH.sub.3                                                              
            H   H   H   -37 ± 8                                        
                                0.5 0.1  0.6     76                       
11  H       CH.sub.3                                                      
                H   H           2   0.3  >10                              
45  CH.sub.3                                                              
            Cl  H   H           0.09                                      
                                    0.012                                 
                                         --      46 ± 8                
12  H       H   H   CH.sub.3                                              
                        -22 ± 10                                       
                                4   3    >10                              
13  OME     H   H   H   -20 ± 14                                       
                                0.5 0.2  4       19                       
14  H       OME H   H   -19 ± 4                                        
                                1   0.2  4       17                       
15  H       H   H   OME -16 ± 3                                        
                                NA  NA                                    
16  OME     OME H   H           0.4      0.7                              
17  H       OME OME H   +26     5        4        0                       
18  H                                                                     
             ##STR24##                                                    
                    H   -25 ± 12                                       
                                0.7 0.07 >50                              
39  CHCH        H   H   -59     --  --   --      --                       
    CHCH                                                                  
__________________________________________________________________________
 ##STR25##                                                                
Position                                                                  
    7       8   9   10                                                    
__________________________________________________________________________
19  H       H   H   H   -32 ± 4                                        
                                25  4                                     
20  Cl      H   H   H   -12 ± 1                                        
                                6   0.7  8                                
21  H       Br  H   H   Toxic   3   1.5  9                                
22  CH.sub.3                                                              
            H   H   H   -26 ± 9                                        
                                3   0.3  >10                              
23  H       CH.sub.3                                                      
                H   H   -7 ± 2                                         
                                16  2                                     
24  H       H   H   CH.sub.3                                              
                        -19     NA   NA                                   
25  OME     H   H   H   5 ± 3                                          
                                2   0.4  8                                
26  H       OME H   H   19 ± 6                                         
                                6   1.5  >10                              
27  H       H   H   OME -1 ± 4                                         
                                NA  NA                                    
28  H       OME OME H   -7 ± 2                                         
                                NA  32                                    
__________________________________________________________________________
 ##STR26##                                                                
Position                                                                  
    6       7   8   9                                                     
__________________________________________________________________________
29  H       H   H   H   -28     2   7    35                               
50  CH.sub.3                                                              
            H   H   H   -49                                               
51  H       CH.sub.3                                                      
                H   H   -34                                               
__________________________________________________________________________
 +Denotes an increase in b.p.                                             
 -Denotes a decrease in b.p.
*In vivo/In vitro testing:
Before dosing the animals, blood samples are taken. The blood is centrifuged to obtain the blood platelet-rich plasma. Aggregation of this plasma is induced with ADP or collagen. This is the control.
The animals are then dosed with the compounds to be tested (orally or parenterally). Depending upon the route of administration, 1 to 2 hours are allowed to elapse after dosing. Blood is drawn and the same procedure employed as for the control in untreated animals.
The dose required to produce 50% inhibition of the aggregation is determined by dose response data obtained in this manner.
Experimental
All products described are supported by satisfactory infrared (IR) and nuclear magnetic resonance (nmr) spectra. Melting points are uncorrected. Temperatures are expressed in degrees Centigrade (°C.) and pressures in millimeters of mercury (mm).
EXAMPLE 1 Preparation of N-(o-Nitrobenzyl)ethyl glycine
To a suspension of 55.9 g. (4.0×10-1 moles) of ethyl glycine hydrochloride in 300 ml. of absolute ethyl alcohol was slowly added (˜5 minutes) under a nitrogen atmosphere a solution of 70 ml. (5.0×10-1 moles) of triethylamine in 200 ml. of absolute ethyl alcohol. The mixture was heated to reflux and a solution of 17.2 g. (1.0×10-1 moles)o-nitrobenzylchloride in 200 ml. of absolute ethyl alcohol was added over a 1.5 hour period. Upon complete addition, the mixture was allowed to reflux for 18 hours, cooled to room temperature and the solvent removed in vacuo. To the solid residue was added 500 ml. of water and enough 10% hydrochloric acid to make the solution acidic (pH˜3). The acidic solution was washed with methylene chloride (2×150 ml.), made neutral (pH˜7) by the addition of saturated sodium bicarbonate and the insoluble oil extracted with methylene chloride (2×250 ml). The methylene chloride extracts were combined, washed with water (250 ml.), dried (K2 CO3) and the solvent removed in vacuo resulting in a yellow oil. Owing to the instability of the oil toward distillation, the compound was used as such in subsequent reaction.
EXAMPLE 2 Preparation of N-(o-Aminobenzyl)ethyl glycine.
To a solution of 13.0 g. (5.46×10-2 moles) of N-(o-nitrobenzyl)ethyl glycine in 200 ml. of absolute ethyl alcohol was added slowly 0.76 g. (5% by weight) of 10% Pd/C catalyst and the mixture placed on a Paar hydrogenator. The mixture was shaken until theoretical hydrogen (16.4×10-2 moles) had been absorbed, removed from the Paar and the mixture filtered under suction. The catalyst was washed with ethyl alcohol and the solvent removed in vacuo affording a yellow oil. Purification of the oil was effected by distillation yielding 8.8 g. (77% yield) of a colorless oil; b.p. 124°-126° C. (0.03 mm).
Anal. calc'd. for C11 H16 N2 O2 :C, 63.44, H, 7.74, N, 13.45. Found: C, 63.57; H, 7.89; N, 13.57.
EXAMPLE 3 Preparation of 1,2,3,5-tetrahydroimidazo [2,1-b]-quinazolin-2-one (1).
To a solution of 6.24 g. (3.0×10-2 moles) of N-(o-aminobenzyl)ethyl glycinate in 150 ml. of 95% ethyl alcohol was poured at room temperature a solution of 3.19 g. (3.0×10-2 moles) of cyanogen bromide in 30 ml. of 95% ethyl alcohol. The mixture was allowed to stir at room temperature for 15 minutes, heated to reflux for 18 hours, cooled to room temperature and the solvent removed in vacuo. To the resulting semi-solid mass was added 200 ml. of water and it was made basic (pH 10) by the addition of a saturated sodium bicarbonate solution. After stirring for 0.5 hours at room temperature, the precipitate was filtered, washed with water and dried under high vacuum/P2 O5 resulting in 3.33 g. (65% yield) of a colorless powder, mp. >285° C. Purification could be effected by crystallization from hot dimethylformamide or by formation of the hydrochloride salt from acetonitrile/ether solvent pair.
1,2,3,5-tetrahydroimidazo-[2,1-b]-quinazolin-2-one hydrochloride: mp. 259°-263° W/decomp.
Anal. calc'd. for C10 H9 N3 O.HCl: C, 53.70; H, 4.51; N, 18.79; Cl, 15.85. Found: C, 53.57; H, 4.79; N, 18.93; Cl, 15.77.
EXAMPLE 4 ##STR27## Preparation of Substituted N-(o-Nitrobenzyl)-Ethyl Glycinates. Glycinates
Substitution in the procedure of Example 1 for the o-nitrobenzyl chloride used therein of an equimolar quantity of the appropriately R1, R2, R3 -substituted o-nitrobenzylchloride produced the compounds having formula III in which n, R1, R2 and R3 are as designated:
______________________________________                                    
Compound                                                                  
No.      R.sup.1 R.sup.2     R.sup.3   n                                  
______________________________________                                    
 2A      H       H           6-Cl      1                                  
 3A      H       H           5-Cl      1                                  
 4A      H       H           4-Cl      1                                  
 5A      H       H           3-Cl      1                                  
 7A      H       H           4-F       1                                  
10A      H       H           6-CH.sub.3                                   
                                       1                                  
11A      H       H           5-CH.sub.3                                   
                                       1                                  
12A      H       H           3-CH.sub.3                                   
                                       1                                  
13A      H       H           6-OCH.sub.3                                  
                                       1                                  
14A      H       H           5-OCH.sub.3                                  
                                       1                                  
15A      H       H           3-OCH.sub.3                                  
                                       1                                  
16A      H       5-OCH.sub.3 6-OCH.sub.3                                  
                                       1                                  
17A      H       4-OCH.sub.3 5-OCH.sub.3                                  
                                       1                                  
18A      H       R.sup.2 and R.sup.3 are methylenedioxy                   
                                     1                                    
19A      H       H           H         2                                  
20A      H       H           6-Cl      2                                  
22A      H       H           6-CH.sub.3                                   
                                       2                                  
23A      H       H           5-CH.sub.3                                   
                                       2                                  
24A      H       H           3-CH.sub.3                                   
                                       2                                  
25A      H       H           6-OCH.sub.3                                  
                                       2                                  
26A      H       H           5-OCH.sub.3                                  
                                       2                                  
  27AA   H       H           3-OCH.sub.3                                  
                                       2                                  
28A      H       4-OCH.sub.3 5-OCH.sub.3                                  
                                       2                                  
29A      CH.sub.3                                                         
                 H           H         1                                  
30A      CH.sub.3                                                         
                 H           H         2                                  
31A      H       3-CH.sub.3  6-CH.sub.3                                   
                                       1                                  
32A      H       H           6-Br      1                                  
33A      H       H           6-F       1                                  
______________________________________
EXAMPLE 5 ##STR28##
Substitution in the procedure of example 2 for the N-(o-nitrobenzyl)ethylglycine used therein of an equimolar quantity of the appropriately R1, R2, R3 -substituted compound III produced the compounds having the formula IV:
__________________________________________________________________________
Com-                                                                      
pound                                                                     
No. n R.sup.1                                                             
         R.sup.2    R.sup.3                                               
                         R.sup.4                                          
                            b.p.(mm.)                                     
                                   % yield                                
__________________________________________________________________________
 2B 1 H  H          6-Cl Et **m.p. 185-                                   
                                   *80 G                                  
                            186° C. as                             
                                   crude                                  
                            2 HCl                                         
 3B 1 H  H          5-Cl Et **     *                                      
 4B 1 H  H          4-Cl Et **     *                                      
 5B 1 H  H          3-Cl Et **     *                                      
 7B 1 H  H          4-F  Et 138° C. (0.35)                         
                                   *63                                    
                                   (crude)                                
10B 1 H  H          6-CH.sub.3                                            
                         Et 170° C. (0.3)                          
11B 1 H  H          5-CH.sub.3                                            
                         Et 129-133° C.                            
                            (0.1)                                         
13B 1 H  H          6-OCH.sub.3                                           
                         Et **                                            
14B 1 H  H          5-OCH.sub.3                                           
                         Et 162-164° C.                            
                                   98                                     
                            (0.3)  (crude)                                
15B 1 H  H          3-OCH.sub.3                                           
                         Et **                                            
16B 1 H  5-OCH.sub.3                                                      
                    5-OCH.sub.3                                           
                         Et **                                            
17B 1 H  4-OCH.sub.3                                                      
                    6-OCH.sub.3                                           
                         Et *m.p. 202-                                    
                                   93                                     
                            203° C.                                
                                   (crude)                                
18B 1 H  R.sup.2 and R.sup.3 are                                          
                         Et **     99                                     
         methylenedioxy            (crude)                                
19B 2 H  H          H    Et m.p. 178-                                     
                                   52                                     
                            180° C. as                             
                            HCl                                           
20B 2 H  H          6-Cl Et m.p. 191-                                     
                                   *                                      
                            193° C. as                             
                            2.HCl                                         
22B 2 H  H          6-CH.sub.3                                            
                         Et m.p. 204-                                     
                            206° C. as                             
                            2.HCl                                         
23B 2 H  H          5-CH.sub.3                                            
                         Me 126-129° C.                            
                            (0.06)                                        
24B 2 H  H          3-CH.sub.3                                            
                         Me 136° C. (0.07)                         
25B 2 H  H          6-OCH.sub.3                                           
                         Me **                                            
26B 2 H  H          5-OCH.sub.3                                           
                         Me **                                            
27B 2 H  H          3-OCH.sub.3                                           
                         Me **                                            
28B 2 H  4-OCH.sub.3                                                      
                    5-OCH.sub.3                                           
                         Me **                                            
29B 1 CH.sub.3                                                            
         H          H    Et **                                            
30B 2 CH.sub.3                                                            
         H          H    Me **                                            
31B 1 H  3-CH.sub.3 6-CH.sub.3                                            
                         Et **     92                                     
32B 1 H  H          6-F  Et **     74                                     
33B 1 H  H          4-CH.sub.3                                            
                         Et M P 182-3° C.                          
                                   78                                     
34B 1 H  H          4-CH.sub.3                                            
                         Et **     97                                     
35B 1 H  4-CH.sub.3 6-CH.sub.3                                            
                         Et **     88                                     
36B 1 H  4-CH.sub.3 5-CH.sub.3                                            
                         Et **     91                                     
37B 1 H  5-CH.sub.3 6-CH.sub.3                                            
                         Et **     99                                     
38B 1 H  H          6-Et Et **     90                                     
39B 1 H  5.6-CH═CH--CH═                                           
                         Et **     92                                     
         CH--                                                             
40B 1 H  4-Cl       6-Cl Et **     92                                     
                                   Example 19                             
41B 1 H  3-Cl       6-Cl Et **     Example 21                             
42B 1 H  H          6-Br Et **     74                                     
                                   Example 18                             
43B 1 H  H          6-CF.sub.3                                            
                         Et **     Example 20                             
__________________________________________________________________________
 *These reductions were carried out in the presence of two equivalents of 
 hydrochloric acid                                                        
 **Compounds could not be distilled used crude in subsequent reactions
EXAMPLE 6 ##STR29##
Substitution in the procedure of example 3 for the N-(o-aminobenzyl)ethyl glycinate used therein of an equimolar quantity of the appropriate compound IV described in example 5 produced the compounds I listed below:
__________________________________________________________________________
Compound                                                                  
No.    n  R.sup.1                                                         
              R.sup.2 R.sup.3 m.p. (HCl)C.°                        
__________________________________________________________________________
 2     1  H   H       6-Cl    245° w/decomp.                       
 3     1  H   H       7-Cl    >250°*                               
 4     1  H   H       8-Cl    251-53° w/decomp.                    
 5     1  H   H       9-Cl    261-64° w/decomp.                    
 7     1  H   H       8-F     280° w/decomp.                       
10     1  H   H       6-CH.sub.3                                          
                              >250°                                
11     1  H   H       7-CH.sub.3                                          
                              265-70° C.                           
12     1  H   H       9-CH.sub.3                                          
                              >280°                                
13     1  H   H       6-OCH.sub.3                                         
                              288-290°                             
14     1  H   H       7-OCH.sub.3                                         
                              267-70° w/decomp.                    
15     1  H   H       9-OCH.sub.3                                         
                              262-264°                             
16     1  H   6-OCH.sub.3                                                 
                      7-OCH.sub.3                                         
                              263-65°*                             
17     1  H   8-OCH.sub.3                                                 
                      7-OCH.sub.3                                         
                              227-28 w/decomp.*                           
18     1  H   R.sup.2 and R.sup.3 are                                     
                              >250°*                               
              7,8-methylene-                                              
              dioxy                                                       
19     2  H   H       H       260-64°*                             
20     2  H   H       7-Cl    >280°*                               
22     2  H   H       7-CH.sub.3                                          
                              >280°*                               
23     2  H   H       8-CH.sub.3                                          
                              269-72° (free base)*                 
24     2  H   H       10-CH.sub.3                                         
                              192-95° (free base)*                 
25     2  H   H       7-OCH.sub.3                                         
                              274-81° decomp.*                     
26     2  H   H       8-OCH.sub.3                                         
                              254-56°*                             
27     2  H   H       10-OCH.sub.3                                        
                              272-74°*                             
28     2  H   9-OCH.sub.3                                                 
                      8-OCH.sub.3                                         
                              269-73°*                             
29     1  CH.sub.3                                                        
              H       H       266-67°*                             
30     2  CH.sub.3                                                        
              H       H       >275°*                               
31     1  H   9-CH.sub.3                                                  
                      6-CH.sub.3                                          
                              >200° decomp.                        
32     1  H   H       6-F     275-280° decomp.                     
33     1  H   H       8-CF.sub.3                                          
                              >275°                                
34     1  H   H       8-CH.sub.3                                          
                              >200° decomp.                        
35     1  H   8-CH.sub.3                                                  
                      6-CH.sub.3                                          
                              >200° decomp.                        
36     1  H   8-CH.sub.3                                                  
                      7-CH.sub.3                                          
                              >200° decomp.                        
37     1  H   7-CH.sub.3                                                  
                      6-CH.sub.3                                          
                              >200° decomp.                        
38     1  H   H       6-Et    >200° decomp.                        
39     1  H   6.7-CH═CH--CH═CH--                                  
                              >275° C.                             
40     1  H   8-Cl    6-Cl     >275° C.                            
41     1  H   9-Cl    6-Cl    >275° C.                             
42     1  H   H       6-Br    >275° C.                             
43     1  H   H       6-CF.sub.3                                          
                              302° C. decomp.                      
__________________________________________________________________________

______________________________________                                    
Compound                                                                  
No.      Analyses                                                         
______________________________________                                    
 2.      Anal. calc'd. for C.sub.10 H.sub.3 ClN.sub.2 O.HCl: C, 46.53;    
         H, 3.51; N, 16.28; Cl, 27.47.                                    
         Found: C, 46.60;                                                 
         H, 3.68; N, 16.14; Cl, 27.32.                                    
 3.      Anal. calc'd. for C.sub.10 H.sub.2 ClN.sub.2 O:                  
         C, 54.19; H, 3.64; N, 18.96; Cl, 16.00.                          
         Found: C, 54.35;                                                 
         H, 3.73; N, 19.19; Cl, 15.87.                                    
 4.      Anal. calc'd. for C.sub.10 H.sub.3 ClN.sub.2 O.HCl.sub.2 H.sub.2 
         O:                                                               
         C, 44.96; H, 3.77; N, 15.73; Cl, 26.54.                          
         Found: C, 45.07; H,                                              
         3.99; N, 15.82, Cl, 25.90.                                       
 5.      Anal. calc'd. for C.sub.10 H.sub.2 ClN.sub.2 O; C, 54.19;        
         H, 3.64; N, 18.96; Cl, 16.00.                                    
         Found: C, 54.35; H,                                              
         3.87; N, 19.22; Cl, 16.18.                                       
 7.      Anal. calc'd for C.sub.10 H.sub.3 FN.sub.1 O HCl                 
         C, 4970; H, 3.75; N, 17.14.                                      
         Found: C, 50.07; H,                                              
         3.86; N, 17.96.                                                  
10.      Anal. calc'd. for C.sub.11 H.sub.11 N.sub.2 O HCl 1/2H.sub.2 O   
         C, 52.41; H, 5.25; N, 16.83; Cl, 14.20                           
         C, 53.20;                                                        
         H, 5.28; N, 17.00; Cl, 14.28;                                    
11.      Anal. calc'd. for C.sub.11 H.sub.11 N.sub.2 O HCl H.sub.2 O      
         C, 51.66; H, 5.52; N, 16.43; Cl, 13.86                           
         Found: C, 52.07.                                                 
         H, 5.74; N, 16.57; Cl, 13.96                                     
12.      Anal. calc'd. for C.sub.11 H.sub.11 N.sub.2 O HCl                
         C, 55.59; H, 5.09; N, 17.68;                                     
         Found: C, 55.59.                                                 
         H, 5.25; N, 17.87                                                
13.      Anal. calc'd. for C.sub.11 H.sub.11 N.sub.2 O.sub.2 HCl          
         C, 52.08; H, 4.77; N, 16.56.                                     
         Found: C, 51.54,                                                 
         H, 4.84; N, 16.69.                                               
14.      Anal. calc'd. for C.sub.11 H.sub.11 N.sub.2 O.sub.2 HCl C,       
         52.08;                                                           
         H, 4.77; N, 16.56; Cl, 13.98;                                    
         Found: C, 51.82,                                                 
         H, 4.92; N, 16.70; Cl, 14.22.                                    
15.      Anal. calc'd. for C.sub.11 H.sub.11 N.sub.2 O.sub.2 HCl          
         1/2H.sub.2 O; C, 50.29; H, 4.99; N, 15.99                        
         Found: C, 50.60;                                                 
         H, 4.99; N, 16.07.                                               
16.      Anal. calc'd. for C.sub.12 H.sub.12 N.sub.2 O.sub.3 HCl          
         C, 50.80; H, 4.97; N, 14.81; - Found: C, 50.64;                  
         H, 5.12; N, 14.51.                                               
17.      Anal. calc'd. for C.sub.12 H.sub.12 N.sub.2 O.sub.3 HCl.1/2      
         H.sub.2 O; C, 49.23; H, 5.17; N, 14.36; Cl, 12.11                
         Found: C, 49.46;                                                 
         H, 4.92; N, 14.48; Cl, 12.28.                                    
18.      Anal. calc'd. for C.sub.11 H.sub.1 N.sub.3 O.sub.2 C,            
         57.14; H, 3.92; N, 18.17.                                        
         Found: C, 57.13;                                                 
         H, 4.01; N, 18.48.                                               
19.      Anal. calc'd. for C.sub.11 H.sub.11 N.sub.2 O; C,                
         65.67; H, 5.51; N, 20.88.                                        
         Found: C, 65.61;                                                 
         H, 5.62; N, 20.70.                                               
20.      Anal. calc'd. for C.sub.11 H.sub.10 ClN.sub.2 O.HCl              
         C, 48.55; H, 4.08; N, 15.44                                      
         Found: C, 48.28;                                                 
         H, 4.37; N, 15.21.                                               
22.      Anal. calc'd. for C.sub.10 H.sub.10 N.sub.2 O.HCl:               
         C, 57.26; H, 5.61; N, 16.69; Cl, 14.08                           
         Found: C, 56.96;                                                 
         H, 5.66; N, 16.90; Cl, 14.15.                                    
23.      Anal. calc'd. for C.sub.10 H.sub.13 N.sub.2 O: C,                
         66.95; H, 6.09; N, 19.52.                                        
         FOund: C, 64.09;                                                 
         H, 6.35; N, 19.40.                                               
24.      Anal. calc'd. for C.sub.12 H.sub. 13 N.sub.2 O: C, 66.95;        
         H, 6.09; N, 19.52.                                               
         Found: C, 66.87; H,                                              
         6.34; N, 19.85.                                                  
25.      Anal. calc'd. for C.sub.12 H.sub.13 N.sub.2 O.sub.2 1/2H.sub.2   
         O:                                                               
         C, 60.01; H, 5.46; N, 17.49.                                     
         Found: C, 60.12; H,                                              
         5.74; N, 17.54.                                                  
26.      Anal. calc'd. for C.sub.12 H.sub.12 N.sub.2 O.sub.2.HCl:         
         C, 53.84; H, 5.27; N, 15.70.                                     
         Found: C, 53.77; H,                                              
         5.47; N, 15.45.                                                  
27.      Anal. calc'd. for C.sub.12 H.sub.12 N.sub.2 O.sub.2.HCl          
         1/2H.sub.2 O:                                                    
         C, 52.08; H, 5.46; N, 15.19.                                     
         Found: C, 51.78; H,                                              
         5.13; N, 15.08.                                                  
28.      Anal. calc'd. for C.sub.12 H.sub.15 N.sub.2 O.sub.3 1/2H.sub.2   
         O:                                                               
         C, 57.77; H, 5.97; N, 15.55.                                     
         Found: C, 57.42; H,                                              
         6.02; N, 15.36.                                                  
29.      Anal. calc'd. for C.sub.11 H.sub.11 N.sub.2 O: C, 65.66          
         H, 5.51; H, 20.88.                                               
         Found: C, 65.40; H,:                                             
         5.56; N, 20.51.                                                  
30.      Anal. calc'd. for C.sub.10 H.sub.12 N.sub.2 O: C, 66.96;         
         H, 6.09; N, 19.52.                                               
         Found: C, 67.07; H,                                              
         6.36; N, 19.34.                                                  
31.      Anal. calc'd. for C.sub.12 H.sub.13 N.sub.2 O.HCl: C,            
         57.26; H, 5.61; N, 16.69; Cl, 14.08.                             
         Found: C, 57.43;                                                 
         H, 5.85; N, 16.70; Cl, 13.75.                                    
32.      Anal. calc'd. for C.sub.10 H.sub.2 FN.sub.2 O.HCl: C,            
         49.70; H, 3.75; N, 17.39.                                        
         Found: C, 49.55;                                                 
         H, 3.98; N, 17.42.                                               
         Anal. calc'd. for C.sub.11 H.sub.3 F.sub.3 N.sub.3 O: C,         
         51.77; H, 3.16; N, 16.47.                                        
         Found: C, 51.70;                                                 
         H, 3.19; N, 16.23.                                               
34.      Anal. calc'd. for C.sub.11 H.sub.11 N.sub.3 O: C, 65.67;         
         H, 5.51; N, 20.88.                                               
         Found: C, 64.79;                                                 
         H, 5.70; N, 20.82.                                               
35.      Anal. calc'd. for C.sub.12 H.sub.12 N.sub.2 O.HCl.H.sub.2 O:     
         C, 53.44; H, 5.98; N, 15.58; Cl, 13.14.                          
         Found: C, 53.71;                                                 
         H, 6.13; N, 15.6; Cl, 12.84.                                     
36.      Anal. calc'd. for C.sub.12 H.sub.13 N.sub.3 O.HCl.H.sub.2 O:     
         C, 53.64; H, 5.63; N, 15.64; Cl, 13.19.                          
         Found: C, 53.91; H,                                              
         5.92; N, 15.75; Cl, 13.36.                                       
37.      Anal. calc'd. for C.sub.12 H.sub.13 N.sub.3 O: C, 66.95;         
         H, 6.09; N, 19.52.                                               
         Found: C, 66.83;                                                 
         H, 6.23; N, 19.30.                                               
38.      Anal. calc'd. for C.sub.12 H.sub.13 N.sub.2 O.HCl: C, 57.26;     
         H, 5.61; N, 16.69; Cl, 14.08.                                    
         Found: C, 56.93; H,                                              
         5.61; N, 16.81; Cl, 14.02.                                       
39.      Anal. calc'd. for C.sub.14 H.sub.11 N.sub.3 O.HCl: C, 61.43;     
         H, 4.42; N, 15.35.                                               
         Found: C, 61.52; H,                                              
         4.96; N, 12.17.                                                  
40.      Anal. calc'd. for C.sub.10 H.sub.7 Cl.sub.2 N.sub.3 O: C,        
         46.90;                                                           
         H, 2.76; N, 16.41.                                               
         Found: C, 46.90; H,                                              
         2.91; N, 16.38.                                                  
41.      Anal. calc'd. for C.sub.10 H.sub.7 Cl.sub.2 N.sub.3 O: C,        
         46.90;                                                           
         H, 2.76; N, 16.41.                                               
         Found: C, 46.64; H,                                              
         3.00; N, 16.39.                                                  
42.      Anal. calc'd. for C.sub.10 H.sub.2 BrN.sub.2 O.HCl: C,           
         39.69; H, 3.00; N, 13.89.                                        
         Found: C, 39.62; H,                                              
         3.17; N, 14.02.                                                  
43.      Anal. calc'd. for C.sub.11 H.sub.2 F.sub.3 N.sub.3 O: C, 51.77;  
         H, 3.16; N, 16.47.                                               
         Found: C, 51.50; H,                                              
         3.41; N, 16.52.                                                  
______________________________________
The IR (infrared) and NMR (nuclear magnetic resonance) spectra of all the compounds were consistent with the structure.
EXAMPLE 7 Ethyl β-(o-Nitrobenzylamino)-propionate (see J.A.C.S., 80, 1168 (1958)
o-Nitrobenzylamine hydrochloride (20.4 g., 0.114 mole) was dissolved in a minimum volume of water and the solution was made strongly basic by addition of 10% sodium hydroxide. The clear oil which formed was extracted into two 120-ml. portions of ether. The ether was dried with 10 g. of anhydrous sodium sulfate, filtered, and finally dried over Drierite. The dried solution was filtered and evaporated, leaving a yellow oil. The oil was dissolved in 100 ml. of absolute ethanol and 11.4 g (0.114 mole) of freshly distilled ethyl acrylate was added. This solution was allowed to stand overnight and the solvent removed by distillation from a steam-cone. The oily residue was dissolved in 200 ml. of dry ether, the solution was cooled in an ice bath, and treated with dry hydrogen chloride. When precipitation was complete, the solid was filtered and dissolved in 120 ml. of boiling absolute ethanol. The hydrochloride crystallized from this solution on cooling yielding 20.7 g. of the aminopropionate hydrochloride, m.p. 137.5°-139.0°. By concentrating and cooling the mother liquor, an additional 5 g. was obtained, m.p. 136.5°-138.5°, and by repeating this operation 1.1 g., m.p. 136°-139°, was obtained, raising the total yield to 26.8 g. (81.4%). The analytical sample was prepared by repeated crystallization from absolute ethanol to give a melting point of 138.5°-139.0°.
Anal. calc'd. for C12 H17 O4 N2 Cl: C, 49.91; H, 5.94; N, 9.70. Found: C, 49.9; H, 5.94; N, 9.51.
EXAMPLE 8 ##STR30##
Substitution in the procedure of example 4 for the o-nitrobenzylamine used therein of an equimolar quantity of the appropriately R1, R2, R3 substituted o-nitrobenzylamine produces compounds III in which R1, R2, R3 - is as defined in the specification.
EXAMPLE 9 Preparation of 7-Bromo-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one
To a vigorously stirred solution of 1.87 g. (0.01 mole) of 1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one in 40 ml. of glacial acetic acid was added dropwise at room temperature 1.60 g. (0.01 mole) of bromine. The mixture was stirred at room temperature for one hour, water (50 ml.) was added and the volume concentrated (10-15 ml.) in vacuo. Additional water (50 ml.) was added, the solution made basic with ammonium hydroxide, warmed and the insoluble material filtered under suction. The colorless solid was washed with water, dried and crystallized from 50 ml. of 5% hydrochloric acid yielding 0.8 g. (30% yield) of a colorless solid: m.p. >275°. Purification was effected by crystallization from methanol/ether; m.p. 275° to yield the title product.
Anal. calc'd. for C10 H8 BrN3 O.HCl: C, 39.70; H, 3.00; N, 13.89.
Found: C, 39.34; H, 3.20; N, 13.88.
EXAMPLE 10 Preparation of 7-Nitro-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-2-one
To a stirred, 0° suspension of 11.20 g. (6.0×10-2 moles) of 1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one in acetonitrile (150 ml.) was added dropwise 83.0 g. (6.6×1012 moles of nitric acid) of a 5% nitric acid/sulfuric acid solution. The mixture was allowed to stir at 0° for 45 minutes, warmed to room temperature and stirred an additional 2 hours. The mixture was poured into 700 ml. of ice water, the organic layer separated, the acidic aquo solution washed with methylene chloride (2×100 ml.) and filtered. The aqueous solution was made basic (pH 8) by the dropwise addition of 40% sodium hydroxide, the basic solution stirred for 30 minutes and the precipitate filtered under suction. The yellow solid was washed with water, then acetone and dried under high vacuum (almost quantitative yield). The solid was suspended in water (350 ml.), the solution saturated with hydrogen chloride, heated to boiling and filtered. Saturated sodium chloride solution (100 ml.) was added, the mixture cooled and the precipitate isolated yielding 6.92 g. (43% yield) of a yellow powder. M.p. >280°: Spectral data was consistent with assigned structure: the 7-Nitro-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one-hydrochloride was used as such in subsequent reaction.
EXAMPLE 11 Preparation of 7-Amino-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-2-one
To a suspension of 9.18 g. (3.4×10-2 mole) of 7-Nitro-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one hydrochloride in 95% ethanol (300 ml.) was added 10 ml. of concentrated hydrochloric acid and 0.45 g. of 10% Pd/C catalyst. The mixture was placed on a Paar hydrogenator, shaken until theoretical hydrogen absorbed, removed and water (150 ml.) added to effect dissolution of precipitate. The mixture was filtered under suction, the catalyst washed with 95% ethanol and the mixture evaporated to dryness yielding 9.02 g. of a yellow powder. Purification of the free base was effected yielding 7-Amino-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one; m.p. >275°.
Anal. calc'd. for C10 H10 N4 O: C, 59.39; H, 4.98; N, 27.71. Found: C, 59.14; H, 5.16; N, 28.03.
EXAMPLE 12 Preparation of 6-Hydroxy-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one
A mixture of 16.0 g. (6.91×10-2 moles) of compound 13 and 750 ml. of 48% aqueous hydrobromic acid was heated to reflux for 22 hours, the mixture cooled by the addition of ice, the precipitate filtered under suction, washed with water and dried. The precipitate was dissolved in a minimum amount of 1N hydrochloric acid, treated with charcoal, filtered and cooled (4°) overnight. The precipitate was isolated and dried yielding 4.65 g. of colorless needles; m.p. >280° to yield the title compound.
Anal. calc'D. for C10 H9 N3 O2.HCl: C, 50.11; H, 4.21; N, 17.53. Found: C, 49.82; H, 4.30; N, 17.33.
EXAMPLE 13 Preparation of 7-Hydroxy-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one
Substitution in the procedure of example 12 for the 6-methoxy-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-2-one-used therein of an equimolar quantity of 7-methoxy-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one produced the title product; m.p. 300° C.
Anal. calc'd. for C10 H9 N3 O2.HCl: C, 50.11; H, 4.21; N, 17.53. Found: C, 50.31; H, 4.46; N, 17.42.
EXAMPLE 14 Preparation of 8-Bromo-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-one
Substitution in the procedure of example 9 for the 1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one used therein of an equimolar quantity of 6-[H]-1,2,3,4-Tetrahydropyrimido[2,1-b]-quinazolin-2-one at about 60° C. produced the title compound, m.p. 267°-269° C. w/decomp.
Anal. calc'd. for C11 H10 BrN3 O 1/3H2 O: C, 46.18; H, 3.76; N, 14.69. Found: C, 46.23; H, 3.63; N, 14.96.
EXAMPLE 15 Preparation of 6-Methyl-7-nitro-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one
Substitution in the procedure of example 10 for the 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one used therein by an equimolar quantity of 6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one produced the title compound; m.p. >300°.
Anal. calc'd. for C11 H10 N4 O3.HCl: C, 46.75; H, 3.92; N, 19.82; Cl, 12.54. Found: C, 46.95; H, 4.10; N, 19.66; Cl, 12.63.
EXAMPLE 16 Preparation of N-(2,3-dimethyl-6-nitrobenzyl)ethyl glycinate
To a mixture of 1.80 g (10 mmole) of 2,3-dimethyl-6-nitrobenzyl amine, 0.60 g (5.6 mmole) of sodium carbonate in 30 ml of dimethylformamide heated to 80° was added dropwise over a 45 min period a solution of 1.25 ml (11 mmole) of ethyl bromoacetate in 10 ml of dimethylformamide. The mixture was allowed to stir at 80° for 16 hr., cooled, 15 ml of water added and the solvent removed in vacuo. The residue was diluted with water, acidified with 10% hydrochloric acid and the acidic solution washed with ether. The acidic aqueous solution was made basic with ammonium hydroxide, extracted with ether, the ethereal extracts combined, washed with water and dried (Na2 SO4). Removal of the solvent in vacuo afforded 2.50 g (93% yield) of a brown solid. Purification was effected by crystallization from methylcyclohexane; m.p. 50°-3°.
Anal. calc'd. for C13 H18 N2 O4 : C, 58.64; H, 6.81; N, 10.52. Found: C, 58.77; H, 7.10; N, 10.40.
EXAMPLE 17 ##STR31##
Substitution in the procedure of example 16 for the 2,3-dimethyl-6-nitrobenzylamine used therein of an equimolar quantity of the appropriately R2, R3 -substituted o-nitrobenzylamine produced the compounds having formula III in which n, R2 and R3 are as designated:
______________________________________                                    
Compound                                 mp                               
No.     R.sup.2    R.sup.3    n   % Yield                                 
                                         (Hcl)                            
______________________________________                                    
33A     H          4-CF.sub.3 1   60     146-8                            
34A     H          4-CH.sub.3 1   77     122-4                            
35A     4-CH.sub.3 6-CH.sub.3 1   79     136-7                            
36A     4-CH.sub.3 5-CH.sub.3 1   47     --                               
37A     5-CH.sub.3 6-CH.sub.3 1   41     50-3*                            
38A     H          6-Et       1   45     154-7                            
39A     2,3-CH═CH--CH═CH--                                        
                          1     72     --                                 
40A     4-Cl       6-Cl       1   65     oil                              
______________________________________                                    
 33A:   Anal. Calc'd. for C.sub.12 H.sub.13 F.sub.3 N.sub.2 O.sub.4.HCl:  
        C, 42.05;                                                         
        H, 4.12; N, 8.17.                                                 
        Found: C, 42.21;                                                  
H, 4.31; N, 8.32. - 34A:                                                  
        Anal. Calc'd. for C.sub.12 H.sub.16 N.sub.2 O.sub.4.HCl: C,       
        49.99;                                                            
        H, 5.94; N, 9.70; Cl, 12.28.                                      
        Found: C, 49.77;                                                  
        H, 6.03; N, 9.77; Cl, 12.58.                                      
 35A:   Anal. Calc'd. for C.sub.12 H.sub.18 N.sub.2 O.sub.4 HCl:C, 51.57; 
        H,                                                                
        6.23; N, 9.26; Cl, 11.71.                                         
        Found: C, 51.54;                                                  
        H, 6.39; N, 9.24; Cl, 11.59.                                      
 37A:   Anal. Calc' d. for C.sub.12 H.sub.18 N.sub.2 O.sub.4 C, 58.64;    
        H,                                                                
        6.81; N, 10.52.                                                   
        Found: C, 58.77;                                                  
        H, 7.10; N, 10.40.                                                
 38A:   Anal. Calc'd. for C.sub.12 H.sub.18 N.sub.2 O.sub.4.HCl: C,       
        51.57;                                                            
        H, 6.32; N, 9.26; Cl, 11.71.                                      
        Found: C, 51.39; H,                                               
        6.32; N, 9.49; Cl, 11.64.                                         
______________________________________
EXAMPLE 18 Preparation of N-(2-amino-6-bromobenzyl)ethyl glycinate
To a stirred 0° solution of 113 g (0.50 moles) of stannous chloride-dihydrate in concentrated hydrochloric acid (125 ml) was added a solution of 31.69 g (0.10 moles) of N-(2-nitro-6-bromobenzyl)-ethyl glycine in concentrated hydrochloric acid (100 ml). After the initial rise in temperature subsided, the ice bath was removed, the mixture stirred for 0.5 hrs. and then warmed (45°-50°) on a steam bath for 1.5 hrs. The mixture was cooled to room temperature, poured into 1 liter of cooled 3.8 M sodium hydroxide, the mixture was rendered alkaline (pH 10) by the addition of 1N sodium hydroxide and extracted with ether. The etheral extracts were combined, washed with water, dried (K2 CO3) and the solvent removed in vacuo affording 21.2 g (74% yield) of an orange oil which solidified on standing; mp 39°-41°.
Anal. Calc'd. for C11 H15 BrN2 O2 : C, 46.00; H, 5.27; N, 9.76. Found: C, 46.21; H, 5.33; N, 10.03.
EXAMPLE 19 Preparation of N-(2-amino-4,6-dichlorobenzyl)ethyl glycinate (40B)
Substitution in the procedure of example 18 for the N-(2-nitro-6-bromobenzyl)ethyl glycine used therein of an equimolar quantity of N-(2-nitro-4,6-dichlorobenzyl)ethyl glycine produced the title product in 92% yield; m.p. 69.5°-70° C.
Anal. Calc'd. for C11 H14 Cl2 N2 O2 : C, 47.67; H, 5.09; N, 10.11. Found: C, 47.73; H, 5.33; N, 10.16.
EXAMPLE 20 Preparation of N-(2-amino-6-trifluoromethylbenzyl)-ethyl glycinate
To a suspension of 7.40 g (53 mmole) of ethyl glycine hydrochloride salt in 100 ml of methylene chloride was added under a nitrogen atmosphere 5.30 g (53 mmole) of triethylamine. To the stirred mixture was added portionwise 3.25 g (13 mmole) of 2-amino-6-trifluoromethylbenzyl chloride hydrochloride and upon complete addition, the mixture was stirred an additional 2 hrs at room temperature. The methylene chloride was removed in vacuo, water added to the residue and the mixture made basic with sodium bicarbonate. The mixture was extracted with ether, the ether extracts combined, washed with water and dried (Na2 SO4). Removal of the solvent in vacuo afforded 3.68 g (99% yield) of a pale yellow oil. The sample was used as such without further purification.
EXAMPLE 21 Preparation of N-(2-amino-3,6-dichlorobenzyl)ethyl glycinate (41B)
Substitution in the procedure of example 20 for the 2-amino-6-trifluoromethylbenzyl chloride hydrochloride used therein of an equimolar quantity of 2-amino-3,6-dichlorobenzyl chloride hydrochloride produced the title product.
EXAMPLE 22 Preparation of 7-Bromo-6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (44)
Substitution in the procedure of example 9 for the 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one used therein of an equimolar quantity of 6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one produced the title product.
Anal. calc'd. for C11 H10 BrN3 O: C, 47.16; H, 3.60; N, 15.00. Found: C, 46.87; H, 3.82; N, 15.26.
EXAMPLE 23 Preparation of 7-Chloro-6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (45)
Substitution in the procedure of example 9 for the 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one and bromine used therein of equimolar quantities of 6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one and chlorine produced the title product.
Anal. calc'd. for C11 H10 ClN3 O.HCl: C, 48.55; H, 4.08; N, 15.44; Cl, 26.05. Found: C, 48.92; H, 4.45; N, 15.64; Cl, 22.38.
EXAMPLE 24 Preparation of 6-Chloro-7-bromo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (46)
To a solution of 1.30 g (8 mmole) of anhydrous ferric chloride in 30 ml of nitromethane was added 1.30 g (5 mmole) of solid 6-chloro-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one and 0.80 g (5 mmole) of bromine. The system was stoppered, warmed to 50° in an oil bath overnight, cooled to room temperature and the solvent removed in vacuo. The resulting solid was suspended in water (50 ml), the mixture made basic (pH 10) with sodium bicarbonate and stirred at room temperature for 20 min. The solid was filtered under suction, washed with water, then isopropyl alcohol and dried yielding 1.9 g (78% yield) of a beige colored powder. Purification was effected by formation of the hydrochloride salt from acetonitrile; mp >275°.
Anal. calc'd. for C10 H7 BrClN3 O.HCl: C, 35.64; H, 2.39; N, 12.47. Found: C, 37.98; H, 2.94; N, 12.70.
Poor analysis is attributed to loss of hydrogen chloride from the salt upon drying.
EXAMPLE 25 Preparation of 6,7-Dichloro-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (47)
Substitution in the procedure of example 24 for the bromine used therein of an equimolar quantity of chlorine produced the title product.
Anal. Calc'd. for C10 H7 Cl2 N3 O.HCl: C, 41.06; H, 2.76; N, 14.36; Cl, 36.36.
Found: C, 42.45; H, 2.95; N, 15.27; Cl, 31.66.
Poor analysis is attributed to loss of hydrogen chloride from the salt upon drying.
EXAMPLE 26 7-Amino-6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (48)
Substitution in the procedure of example 11 for the 7-nitro-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one used therein of an equimolar quantity of 7-nitro-6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one produced the title product; m.p. >260° C.
Anal. calc'd. for C11 H12 N4 O.2HBr: C, 34.94; H, 3.73; N, 14.82. Found: C, 35.01; H, 4.02; N, 14.69.
EXAMPLE 27 Preparation of 6,7-Dihydroxy-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (49)
Substitution in the procedure of example 12 for the 6-methoxy-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one and 750 ml of 48% aqueous hydrobromic acid used therein of an equimolar quantity of 6,7-dimethoxy-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one and 1500 ml of 48% aqueous hydrobromic acid produced the title compound; m.p. >250° C.
Anal. Calc'd. for C10 H9 N3 O3.HCl.1/2H2 O: C, 45.38; H, 4.19; N, 15.88. Found: C, 45.52; H, 4.04; N, 16.39.
EXAMPLE 28 Preparation of 2-methyl-6-nitrobenzyl alcohol.
To a 0° solution of 54.30 g (0.30 moles) of 2-methyl-6-nitrobenzoic acid in 500 ml of anhydrous tetrahydrofuran was added dropwise under a nitrogen atmosphere, 380 ml (0.38 moles) of a stock IM boran/THF solution at such a rate that the temperature did not exceed 5°. Upon complete addition, the ice bath was removed, the solution allowed to stir at room temperature for 14 hours, heated to reflux for 4 hrs. and then cooled to 0° in an ice bath. The reaction was quenched by the dropwise addition of 400 ml of 10% hydrochloric acid, the solution heated to reflux on a steam bath for 0.5 hrs., the THF solvent distilled at atmospheric pressure and the insoluble precipitate extracted into methylene chloride. The methylene chloride extracts were combined, washed with satd. sodium bicarbonate solution, dried (Na2 SO4) and the solvent removed in vacuo affording a reddish colored semi solid. Purification was effected from 300 ml of carbon tetrachloride resulting in 41.35 g (84% yield) of yellow flakes; mp 67°-8°.
Anal. calc'd. for C8 H9 NO3 : C, 57.48; H, 5.43; N, 8.38. Found: C, 57.34; H, 5.42; N, 8.47.
EXAMPLE 29 Preparation of 2-Methyl-6-nitrobenzyl chloride
To a solution of 100 g (0.60 mole) of 2-methyl-6-nitro-benzyl alcohol and 5 ml of pyridine in 1.5 l of benzene was added dropwise 87 ml (1.2 mole) of neat thionyl chloride. The solution was heated to reflux for 2 hr, cooled to 0° and the reaction quenched by the slow addition of 500 ml of water. The organic phase was separated, washed with dilute sodium bicarbonate, dried (Na2 SO4) and the solvent removed in vacuo. The resulting solid was crystallized from 600 ml of cyclohexane yielding 100 g (90% yield) of a colorless solid mp 55°-6°: strong lachrymator and skin irritant.
Anal. calc'd. for C8 H8 ClNO2 : C, 51.76; H, 4.34; N, 7.55; Cl, 19.10. Found: C, 51.99; H, 4.39; N, 7.61; Cl, 19.21.
EXAMPLE 30 Preparation of 2-bromo-6-nitrobenzyl bromide
To a solution of 57.4 g (0.27 mole) of 2-bromo-6-nitro toluene in 800 ml of carbon tetrachloride was added 52.0 g (0.29 mole) of N-bromosuccinimide and 2.5 g of benzoyl peroxide. The mixture was heated to reflux for 64 hr., cooled and filtered. Removal of the solvent in vacuo afforded 86.1 g of a viscous oil. Purification was effected by washing through alumina (CCl4 /ether) and crystallization from ethyl alcohol; mp 61.5°-63°.
Anal. calc'd. for C7 H5 Br2 NO2 : C, 28.50; H, 1.71; N, 4.75. Found: C, 28.86; H, 1.92; N, 4.85.
EXAMPLE 31 Preparation of 2,3-dimethyl-6-nitrobenzylamine
To a solution of 5.70 g (32.4 mmole) of 2,3-dimethyl-6-nitrobenzonitrile in 35 ml of anhydrous tetrahydrofuran was added dropwise under nitrogen 65 ml (65.0 mmole) of a stock IM borane/THF solution. After stirring at room temperature for 19 hr., the solution was cooled to 0° in an ice bath and the reaction quenched by the dropwise addition of 75 ml of 10% hydrochloric acid. The solution was heated to reflux for 0.5 hr., the tetrahydrofuran distilled at atmospheric pressure and the solid removed by filtration. The acidic aqueous solution was washed with ether, made basic with ammonium hydroxide and extracted with ether. The etheral extracts were combined, washed with water, dried (K2 CO3) and the solvent removed in vacuo affording 3.6 g (62% yield) of a brownish colored oil. Purification could be effected by preparation of the hydrochloride salt: mp >225 w/decomp. (EtOH).
Anal. calc'd. for C9 H12 N2 O2.HCl: C, 49.89; H, 6.05; N, 12.93; Cl, 16.36. Found: C, 50.02; H, 6.05; N, 12.94; Cl, 16.08.
EXAMPLE 32 ##STR32##
Substitution in the procedure of example 30 for the 2,3-dimethyl-6-nitrobenzonitrile used therein of an equimolar quantity of the appropriately R2, R3 -substituted 6-nitrobenzonitrile produced the compounds having formula XX in which R2 and R3 are as designated:
______________________________________                                    
R.sup.2    R.sup.3     % Yield  M.P.                                      
______________________________________                                    
H          4-CF.sub.3  28       190-2° C.                          
H          4-CH.sub.3  72       122-4° C.                          
2-CH.sub.3 4-CH.sub.3  77*      >200° C.(d)                        
3-CH.sub.3 4-CH.sub.3  59*      >230° C.(d)                        
2-CH.sub.3 3-CH.sub.3  62*      >230° C.(d)                        
H          2-Et        59*      >230° C.(d)                        
2-Cl       4-Cl        67       oil                                       
2,3-CH═CH--CH═CH--                                                
                   2.3       89-91° C.                             
______________________________________                                    
 *as the HCl salt.
4-CF3 Anal. calc'd. for C8 H7 F3 N2 O2. HCL: C, 37.45; H, 3.14; N, 10.92. Found: C, 37.54; H, 3.18; N, 11.23.
2,4-diMe Anal. calc'd. for C9 H12 N2 O2. HCL: C, 49.89; H, 6.05; N, 12.93; Cl, 16.36.
Found: C, 49.85; H, 6.03; N, 13.09; Cl, 16.25.
3,4-diMe Anal. calc'd. for C9 H12 N2 O2.HCl: C, 49.89; H, 6.05; N, 12.93; Cl, 16.36. Found: C, 50.06; H, 6.19; N, 12.98; Cl, 15.98. 2,3-diMe Anal. calc'd. for C9 H12 N2 O2. HCl: C, 49.89; H, 6.05; N, 12.93; Cl, 16.36. Found: C, 50.02; H, 6.05; N, 12.94; Cl, 16.08. 2-Et Anal. calc'd. for C9 H12 N2. HCL: C, 49.89; H, 6.05; N, 12.93; Cl, 16.36. Found: C, 49.60; H, 6.11; N, 13.00; Cl, 16.26. 2,3--CH═CH--CH═CH-- Anal. calc'd. for C11 H10 N2 O2 : C, 65.33; H, 4.98; N, 13.86. Found: C, 65.63; H, 5.24; N, 13.67.
EXAMPLE 33 Preparation of 2-Amino-6-trifluoromethylbenzyl alcohol
To 25 ml (25 mmole) of a 1M lithium aluminum hydride/tetrahydrofuran stock solution was added dropwise under a nitrogen atmosphere a solution of 5.04 g (23 mmole) of 6-trifluoromethyl anthranilic acid in 25 ml of tetrahydrofuran. After the initial vigorous reaction subsided, the mixture was heated to reflux for 18 hrs., cooled and the reaction quenched by the dropwise addition of 1.9 ml of water and 1.5 ml of 10% aqueous sodium hydroxide solution. The mixture was stirred at room temperature for 1.5 hrs., the solid filtered under suction and washed with ether. Removal of the solvent in vacuo from the filtrate afforded a crystalline solid which was purified by formation of the hydrochloride salt (MeOH/ether) yielding 4.06 g (77% yield) of a colorless solid: mp 150°-1°. Anal. calc'd. for C8 H8 NOF3.HCl: C, 42.21; H, 3.98; N, 6.15. Found: C, 42.17; H, 4.28; N, 6.02.
EXAMPLE 34 Preparation of 2-Amino-6-trifluoromethylbenzyl chloride
To 4.06 g (7.8 mmole) of 2-amino-6-trifluoromethylbenzyl alcohol in a pressure bottle was added 60 ml of concentrated hydrochloric acid, the bottled stoppered and immersed in an oil bath maintained at 100°. The mixture was stirred for 1.5 hr., cooled and the precipitate filtered under suction. The colorless solid was washed with water and dried under high vacuum, yielding 3.28 g (75% yield) of a colorless solid; mp 155°-161°. The sample was used as such without further purification.
EXAMPLE 35 Preparation of 2,5-Dimethyl-6-nitrobenzyl alcohol
Substitution in the procedure of example 28 for the 2-methyl-6-nitrobenzoic acid used therein of an equimolar quantity of 2,5-dimethyl-6-nitrobenzoic acid produced the title compound in 81% yield.
EXAMPLE 36 Preparation of 2,5-Dimethyl-6-nitrobenzyl chloride
Substitution in the procedure of example 29 for the 2-methyl-6-nitrobenzyl alcohol used therein of an equimolar quantity of 2-fluoro-6-nitrotoluene produced the title product in 52% yield.
EXAMPLE 37 Preparation of 2-amino-3,6-dichlorobenzyl alcohol.
Substitution in the procedure of example 33 for the 6-trifluoromethylanthranilic acid used therein of an equimolar quantity of 3,6-dichloroanthranilic acid produced the title product in 72% yield; m.p. 96°-97° C.
Anal. calc'd. for C7 H7 Cl2 NO: C, 43.78; H, 3.67; N, 7.30. Found: C, 43.59; H, 3.80; N, 7.49.
EXAMPLE 38 Preparation of 2-amino-3,6-dichlorobenzyl chloride
Substitution in the procedure of example 34 for the 2-amino-6-trifluoromethylbenzyl alcohol used therein of an equimolar quantity of 2-amino-3,6-dichlorobenzyl alcohol produced the title product.
EXAMPLE 39 Preparation of 6-methyl-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-2-one (10)
To a 0° solution of 1.06 g (6.64 mmole) of bromine in 0.1 ml of water was added dropwise with stirring a solution of 0.367 g (7.50 mmole) of sodium cyanide in 2.6 ml of water. Upon complete addition, the reaction was stirred in the cold for 1.25 hr., removed from the ice bath, allowed to warm to room temperature (15 min) and 12 ml of absolute ethyl alcohol added. To this solution was added a solution of 1.32 g (5.97 mmole) of N-(2-amino-6-methylbenzyl)ethyl glycinate in 15 ml of absolute ethyl alcohol, the mixture allowed to stir at room temperature for 20 min. and heated slowly to reflux. After 18 hrs., of reflux, the solution was cooled and the solvent removed. To the resulting solid was added 30 ml. of water, the mixture made basic (pH-12) by the addition of concentrated ammonium hydroxide and the mixture allowed to stir for 30 mins. at room temperature. The precipitate was filtered, washed with water and dried yielding 0.93 g (77% yield) of 6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one. Purification was effected by formation of the hydrochloride salt (30 ml of 1N HCL/1 g of product).
EXAMPLE 40 Preparation of 3-(carbethoxymethyl)-3,4-dihydro-5-methyl-4-methylene-1H-quinazolin-2-one
To a solution of 22.4 g (0.15 mole) of 2-amino-6-methylacetophenone in toluene (750 ml) was added a solution of 19.4 g (0.15 mole) of ethyl isocyanatoacetate in toluene (150 ml). The system was fitted with a Dean-Stark trap and the solution heated to reflux. After the theoretical removal of water (3 hrs), the solution was cooled to 0° overnight. The solution was filtered, the precipitate washed with cold toluene and dried yielding 33.9 g (87% yield) of colorless crystals. Purification was effected by recrystallization from toluene; m.p. 151°-4°.
Anal. Calc'd. for C14 H16 N2 O3 : C, 64.60; H, 6.20; N, 10.76. Found: C, 64.75; H, 6.24; N, 11.04.
EXAMPLE 41 Preparation of 3-(carbethoxymethyl)-4,5-dimethyl-1,2,3,4-tetrahydroquinazolin-2-one
To a suspension of 11.0 g (42 mmole) of 3-(carbethoxymethyl)-3,4-dihydro-5-methyl-4-methylene-1-H-quinazolin-2-one in 200 ml of 95% ethyl alcohol was added 1.0 g of 10% Pd/C catalyst and the mixture placed on a Paar hydrogenator. After the theoretical hydrogen absorption, the solution was filtered under suction, the catalyst washed with ethyl alcohol and the solvent removed in vacuo affording 10.9 g (98% yield) of a colorless solid identified as the title compound.
EXAMPLE 42 Preparation of 2-chloro-3-carbethoxymethyl-4,5-dimethyl-3,4-dihydroquinazoline
A mixture of 4.00 g (15.4 mmole) of 3-(carbethoxymethyl)-4,5-dimethyl-1,2,3,4-tetrahydroquinazolin-2-one and 40 ml of phosphorus oxychloride was immersed in an oil bath (100°) for 1.5 hr. The solution was cooled, the excess phosphorus oxychloride removed under aspirator pressure and the residue dissolved in chloroform (100 ml). The chloroform solution was washed with an aqueous saturated sodium bicarbonate solution until the wash was neutral, the chloroform extract separated, dried (Mg SO4) and the solvent removed in vacuo affording 4.5 g of an oil. The spectral data was consistent with the title compound and the compound was used as such.
EXAMPLE 43 Preparation of 5,6-dimethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (50)
To a solution of 4.3 g (15.4 mmole) of 2-chloro-3-(carbethoxymethyl)-4,5-dimethyl-3,4-dihydroquinazoline in 50 ml of absolute ethanol was added a solution of 2.0 g (120 mmole) of ammonia in 25 ml of absolute ethanol, the system was stoppered and immersed in an oil bath (100°). After 16 hrs. of heating, the solution was cooled, the solvent removed in vacuo and the residue crystallized from 1N hydrochloride acid affording 2.29 g (59% yield) of yellow crystals mp 235°-40°.
Anal. calc'd. for C12 H13 N3 O.HCl: C, 57.26; H, 5.61; N, 16.69. Found: C, 57.08; H, 5.56; N, 16.82.
EXAMPLE 44 Preparation of 3-(carbethoxymethyl)-3,4-dihydro-6-methyl-4-methylene-1-H-quinazolin-2-one
Substitution in the procedure of example 40 for the 2-amino-6-methylacetophenone used therein of an equimolar quantity of 2-amino-5-methylacetophenone produced the title compound; m.p.
Anal. Calc'd. for C14 H16 N2 O3 : C, 64.60; H, 6.20; N, 10.76. Found: C, 64.89; H, 6.26; N, 10.99.
EXAMPLE 45 Preparation of 3-(carbethoxymethyl)-4,6-dimethyl-1,2,3,4-tetrahydroquinazolin-2-one
Substitution in the procedure of example 41 for the 3-(carbethoxymethyl)-3,4-dihydro-5-methyl-4-methylene-1-H-quinazolin-2-one used therein of an equimolar quantity of 3-(carbethoxymethyl)-3,4-dihydro-6-methyl-4-methylene-1-H-quinazolin-2-one produced the title product; m.p. 113°-114.5° C.; 98% yield.
Anal. calc'd. for C14 H16 N2 O3 : C, 64.10; H, 6.92; N, 10.68. Found: C, 64.56; H, 6.87; N, 10.97.
EXAMPLE 46 Preparation of 2-chloro-3-carbethoxymethyl-4,6-dimethyl-3,4-dihydroquinazoline
Substitution in the procedure of example 42 for the 3-(carbethoxymethyl)-4,5-dimethyl-1,2,3,4-tetrahydroquinazolin-2-one used therein of an equimolar quantity of 3-(carbethoxymethyl)-4,6-dimethyl-1,2,3,4-tetrahydroquinazolin-2-one produced the title compound as an oil which was used as such in the next example.
EXAMPLE 47 Preparation of 5,7-Dimethyl-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-2-one (51).
Substitution in the procedure of example 43 for the 2-chloro-3-(carbethoxymethyl)-4,5-dimethyl-3,4-dihydro-quinazolin used therein of an equimolar quantity of 2-chloro-3-(carbethoxymethyl)-4,6-dimethyl-3,4-dihydro-quinazoline produced the title product; m.p. 265°-70° C. in 47% yield.
Anal. calc'd. for C12 H13 N3 O.HCl: C, 57.26; H, 5.61; N, 16.69. Found: C, 57.12; H, 5.62; N, 16.42.
EXAMPLE 48 Preparation of 5-methyl-3-(carbethoxymethyl)-1,2,3,4-tetrahydroquinazolin-2-one
To a cooled solution of 15.00 g (67 mmole) of N-(2-amino-6-methyl benzyl) glycine ethyl ester in 300 ml of anhydrous tetrahydrofuran under a nitrogen atmosphere was added a solution of 11.72 g (72 mmole) of 1,1'-carbonyldiimidazole in 200 ml of anhydrous tetrahydrofuran at such a rate that the temperature did not exceed 5°. Upon complete addition, the solution was allowed to stir at room temperature for 2 hours, heated to reflux for 18 hours, cooled to room temperature and the tetrahydrofuran removed in vacuo. The residue was dissolved in methylene chloride (250 ml), washed with 5% aqueous hydrochloric acid (2×100 ml), then water (100 ml). The methylene chloride extract was dired (Na2 SO4) and the solvent removed in vacuo affording 14.0 g (83% yield) of a colorless solid. purification was effected by crystallization from nitromethane; m.p.; 184°-5°.
Anal. calc'd. for C13 H16 N2 O3 : C, 62.89; H, 6.50; N, 11.28. Found; C, 62.85; H, 6.45; N, 11.22.
EXAMPLE 49 Preparation of 2-Chloro-3-carbethoxymethyl-5-methyl-3,4-dihydroquinazoline hydrochloride
A mixture of 2.45 g (10 mmole) of 5-methyl-3-carbethoxymethyl-1,2,3,4-tetrahydroquinazolin-2-one and 20 ml of phosphorus oxychloride was immersed in an oil bath (105°-110°) for 3.5 hrs. The solution was cooled, the excess phosphorus oxychloride removed under aspirator pressure and the residue dissolved in chloroform (50 ml). ice water was added, the mixture shaken and Ice % sodium hydroxide was added dropwise to attain a pH=6. The above process was repeated until a pH=6 was maintained after shaking, the chloroform extract was separated, dried (Na2 SO4) and the solvent saturated with hydrogen chloride gas and the mixture heated to gentle boiling for 10 minutes. The mixture was filtered while hot and the precipitate dried yielding 2.11 g (70% yield) of a pale yellow powder. Purification was effected by crystallization from acetonitrile; m.p. 199-201.
Anal. calc'd. for C13 H15 ClN2 O2 HCl: C, 51.52, H, 5.28; N, 9.24. Found: C, 51,87; H, 5.28; N, 9.27.
EXAMPLE 50 Preparation of 6-methyl-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-2-one (10)
To a solution of 0.60 g (2 mmole) in 20 ml of absolute ethyl alcohol was added 1.36 g (4 mmole) of a 5% ammonia/ethyl alcohol stock solution, the system stoppered and immersed in an oil bath (100°). After 16 hrs. of heating, the solution was cooled, the solvent removed in vacuo and the residue suspended in water (30 ml). The mixture was made basic (pH9) by the addition of saturated sodium bicarbonate solution, the mixture stirred at room temperature and filtered. The precipitate was washed with water, then isopropyl alcohol and dried yielding 0.32 g (80% yield) of a colorless powder. The spectral properties (ir and nmr) were identical to the known 6-methyl-1,2,3,5-tetrahydroimidazo [2,1-b]quinazolin-2-one (see example 6).

Claims (24)

We claim:
1. The compound having the formula ##STR33## in which R1 is H, phenyl or (lower)alkyl, R2 and R3 when different are hydrogen, chloro, bromo, fluoro, CF3, SO3 H, hydroxy, (lower)alkyl or (lower) alkoxy, nitro, amino or phenyl, R2 and R3 when alike are hydrogen, bromo, chloro, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R2 and R3 are methylenedioxy or the moiety --CH═CH--CH═CH--, and n is an integer of 1 or 2; or a pharmaceutically acceptable acid addition salt thereof.
2. The compound of claim 1 having the formula ##STR34## in which R1 is H, phenyl or (lower)alkyl, R2 and R3 when different are hydrogen, chloro, bromo, fluoro, CF3, SO3 H, hydroxy, (lower)alkyl or (lower)alkoxy or phenyl, R2 and R3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R2 and R3 are methylenedioxy or the moiety --CH═CH--CH═C--, and n is an integer of 1 or 2; or a pharmaceutically acceptable acid salt thereof.
3. The compound of claim 1 having the formula ##STR35## in which R1 is H, phenyl or (lower)alkyl, R2 and R3 when different are hydrogen, chloro, bromo, CF3, SO3 H, fluoro, hydroxy, nitro, amino, phenyl, (lower)alkyl or (lower)alkoxy, R2 and R3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R2 and R3 are methylenedioxy or the moiety --CH═CH--CH═CH--; or a pharmaceutically acceptable acid addition salt thereof.
4. The compound of claim 3 having the formula ##STR36## in which R2 and R3 when different are hydrogen, chloro, bromo, fluoro, nitro, amino, CF3, SO3 H, hydroxy, (lower)alkoxy or (lower)alkyl, R2 and R3 when alike are hydrogen, chloro, bromo, fluoro, hydroxy, (lower)alkyl of 1 to 3 carbon atoms or (lower)alkoxy of 1 to 3 carbon atoms, or when taken together R2 and R3 are methylenedioxy or the moiety --CH═CH--CH═CH--; or a pharmaceutically acceptable acid addition salt thereof.
5. The compound of claim 2 having the formula ##STR37## in which R2 and R3 are alike or different and are H, hydroxy, (lower)alkoxy of 1 to 3 carbon atoms or (lower)alkyl of 1 to 3 carbon atoms, chloro, or fluoro; or a pharmaceutically acceptable salt thereof.
6. The compound of claim 2 having the formula ##STR38## in which R2 and R3 are alike or different and each is H, Cl, methoxy, methyl or hydroxy; or the hydrochloride salt thereof.
7. The compound of claim 6 in which R2 and R3 are hydrogen; or the hydrochloride salt thereof.
8. The compound of claim 6 in which R2 and R3 are methoxy; or the hydrochloride salt thereof.
9. The compound of claim 6 in which R2 and R3 are methyl; or the hydrochloride salt thereof.
10. The compound of claim 6 in which R2 is H and R3 is methoxy; or the hydrochloride salt thereof.
11. The compound of claim 6 in which R2 is methoxy and R3 is hydrogen; or the hydrochloride salt thereof.
12. The compound of claim 6 in which R2 is hydrogen and R3 is methyl; or the hydrochloride salt thereof.
13. The compound of claim 6 in which R2 is methyl and R3 is hydrogen; or the hydrochloride salt thereof.
14. The compound of claim 4 in which R2 is nitro and R3 is methyl; or the hydrochloride salt thereof.
15. The compound of claim 4 in which R2 and R3 when taken together are --CH═CH--CH═CH--; or the hydrochloride salt thereof.
16. The compound having the formula ##STR39## or an acid addition salt thereof.
17. The hydrochloride salt of the compound of claim 16.
18. The compound having the formula ##STR40## or an acid addition salt thereof.
19. The hydrochloride salt of the compound of claim 18. .Iadd. 20. The compound having the formula ##STR41##
or an acid addition salt thereof. .Iaddend..Iadd. 21. The compound having the formula ##STR42##
or an acid addition salt thereof. .Iaddend..Iadd. 22. The compound having the formula ##STR43##
or an acid addition salt thereof. .Iaddend..Iadd. 23. The compound having the formula ##STR44##
or an acid additon salt thereof. .Iaddend..Iadd. 24. The compound having the formula ##STR45##
or an acid addition salt thereof. .Iaddend..Iadd. 25. The compound having the formula ##STR46## or an acid addition salt thereof. .Iaddend.
US06/421,501 1972-02-04 1982-09-22 Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones Expired - Lifetime USRE31617E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US06/421,501 USRE31617E (en) 1972-02-04 1982-09-22 Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22372372A 1972-02-04 1972-02-04
US29145072A 1972-09-22 1972-09-22
US05/521,306 US3932407A (en) 1973-11-19 1974-11-06 Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US06/421,501 USRE31617E (en) 1972-02-04 1982-09-22 Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US41689173A Continuation-In-Part 1973-11-19 1973-11-19
US05/521,306 Reissue US3932407A (en) 1972-02-04 1974-11-06 Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones

Publications (1)

Publication Number Publication Date
USRE31617E true USRE31617E (en) 1984-06-26

Family

ID=27499330

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/421,501 Expired - Lifetime USRE31617E (en) 1972-02-04 1982-09-22 Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones

Country Status (1)

Country Link
US (1) USRE31617E (en)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670434A (en) 1985-11-14 1987-06-02 Syntex (U.S.A.) Inc. (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors
US4690925A (en) 1984-02-15 1987-09-01 Syntex (U.S.A.) Inc. (2-Oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl) oxyalkylamides properties having phosphodiosterase inhibiting
US4837239A (en) 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5801245A (en) * 1995-12-04 1998-09-01 Roberts Laboratories Inc. Process for the preparation of ethyl-N-(2,3 dichloro-6-nitrobenzyl) glycine
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6194420B1 (en) 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6306889B1 (en) 1997-09-03 2001-10-23 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6348475B1 (en) 2000-06-01 2002-02-19 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
US6376242B1 (en) 1999-09-21 2002-04-23 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6545011B2 (en) 2000-07-13 2003-04-08 Guilford Pharmaceuticals Inc. Substituted 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones, derivatives thereof and their uses
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
US20040209907A1 (en) * 2003-01-23 2004-10-21 Richard Franklin Formulation and methods for the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US20060052601A1 (en) * 2004-08-04 2006-03-09 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20080176875A1 (en) * 2006-11-28 2008-07-24 Shire Llc Substituted quinazolines
US20080176877A1 (en) * 2006-11-28 2008-07-24 Shire Llc Substituted quinazolines
WO2009138795A1 (en) 2008-05-16 2009-11-19 Shire Llc Substituted quinazolines
US20090324710A1 (en) * 2008-06-16 2009-12-31 Glidden Paul F Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100305318A1 (en) * 2007-12-19 2010-12-02 Watson Pharma Private Limited Process for the Manufacture of Anagrelide Hydrochloride Monohydrate
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
US20110071173A1 (en) * 2008-05-16 2011-03-24 Shire Llc Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases
US20110071172A1 (en) * 2008-05-16 2011-03-24 Shire Llc Substituted quinazolines as blood platelet lowering agents
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20110112236A1 (en) * 2009-11-12 2011-05-12 Kraton Polymers U.S. Llc Thermoplastic polyurethane block copolymer compositions
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
WO2011114160A1 (en) 2010-03-18 2011-09-22 Shire Llc Anagrelide derivatives (imidazo [2, 1-b] quinazolin - 2 - ones ) as pde iii inhibitors useful as antithrombotic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2012052781A1 (en) 2010-10-21 2012-04-26 Shire, Llc Process for the preparation of anagrelide and analogues thereof
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048587A (en) * 1960-10-17 1962-08-07 Ortho Pharma Corp 2-alkylamino-4-aminopyrimidine
US3257401A (en) * 1964-06-18 1966-06-21 Searle & Co 5-hydroxy-2-methylcycloalkyl[d] imidazo[1, 2-a]pyrimidines
US3329679A (en) * 1965-12-22 1967-07-04 American Home Prod Fused-ring imidazoquinazolines, pyrimidoquinazolines and related compounds
DE2025248A1 (en) * 1969-05-28 1970-12-03
US3562272A (en) * 1969-04-15 1971-02-09 Sandoz Ag Preparation of 4-aryl-2(1h)-quinazolinones
US3563990A (en) * 1969-03-18 1971-02-16 Sandoz Ag 1-substituted-4-aryl-2(1h)-quinazolinones
US3594376A (en) * 1969-09-05 1971-07-20 American Home Prod Process for preparing 4-phenylquinazoline-2(1h)-ones
US3600390A (en) * 1968-07-01 1971-08-17 Schering Corp Novel 5-phenyl imidazolidino(5,1-a)5h-quinazolines and process therefor
US3621025A (en) * 1969-12-18 1971-11-16 Smith Kline French Lab Imidazo and pyrimido{8 2,1-{11 {9 quinazoline compounds
US3642897A (en) * 1968-12-26 1972-02-15 Sandoz Ag Preparation of 2-alkylaminobenzophenones
US3660322A (en) * 1968-11-26 1972-05-02 Farmaceutici Italia Benzene-ring-substituted tetrahydro-quinazolines
US3745216A (en) * 1969-12-18 1973-07-10 Smith Kline French Lab Compositions and methods for producing hypotensive activity with imidazo and pyrimido(2,1-b)quinazoline compounds
DE2305575A1 (en) * 1972-02-04 1973-08-09 Bristol Myers Co NEW BLOOD PRESSURE LOWERING AGENTS AND METHODS FOR PRODUCING THEM
US3790576A (en) * 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
US3833588A (en) * 1972-04-25 1974-09-03 Sandoz Ag Unsaturated-substituted tricyclic quinazolinones
US3859289A (en) * 1973-01-26 1975-01-07 Goetz E Hardtmann Tricyclic pyrimidinones

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048587A (en) * 1960-10-17 1962-08-07 Ortho Pharma Corp 2-alkylamino-4-aminopyrimidine
US3257401A (en) * 1964-06-18 1966-06-21 Searle & Co 5-hydroxy-2-methylcycloalkyl[d] imidazo[1, 2-a]pyrimidines
US3329679A (en) * 1965-12-22 1967-07-04 American Home Prod Fused-ring imidazoquinazolines, pyrimidoquinazolines and related compounds
US3600390A (en) * 1968-07-01 1971-08-17 Schering Corp Novel 5-phenyl imidazolidino(5,1-a)5h-quinazolines and process therefor
US3660322A (en) * 1968-11-26 1972-05-02 Farmaceutici Italia Benzene-ring-substituted tetrahydro-quinazolines
US3642897A (en) * 1968-12-26 1972-02-15 Sandoz Ag Preparation of 2-alkylaminobenzophenones
US3563990A (en) * 1969-03-18 1971-02-16 Sandoz Ag 1-substituted-4-aryl-2(1h)-quinazolinones
US3562272A (en) * 1969-04-15 1971-02-09 Sandoz Ag Preparation of 4-aryl-2(1h)-quinazolinones
US3598823A (en) * 1969-05-28 1971-08-10 Sandoz Ag Tricyclic quinazolinones
DE2025248A1 (en) * 1969-05-28 1970-12-03
US3594376A (en) * 1969-09-05 1971-07-20 American Home Prod Process for preparing 4-phenylquinazoline-2(1h)-ones
US3621025A (en) * 1969-12-18 1971-11-16 Smith Kline French Lab Imidazo and pyrimido{8 2,1-{11 {9 quinazoline compounds
US3745216A (en) * 1969-12-18 1973-07-10 Smith Kline French Lab Compositions and methods for producing hypotensive activity with imidazo and pyrimido(2,1-b)quinazoline compounds
DE2305575A1 (en) * 1972-02-04 1973-08-09 Bristol Myers Co NEW BLOOD PRESSURE LOWERING AGENTS AND METHODS FOR PRODUCING THEM
US3790576A (en) * 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
US3833588A (en) * 1972-04-25 1974-09-03 Sandoz Ag Unsaturated-substituted tricyclic quinazolinones
US3859289A (en) * 1973-01-26 1975-01-07 Goetz E Hardtmann Tricyclic pyrimidinones

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
Beverung et al.; J. Md. Chem., 18, pp. 224 225, (1975). *
Beverung et al.; J. Md. Chem., 18, pp. 224-225, (1975).
Born, Proc. Phys. Soc. 162, 67P 68P, (1962). *
Born, Proc. Phys. Soc. 162, 67P-68P, (1962).
Cox et al.; J. Chem. Soc., pp. 2134 2136 (1970). *
Cox et al.; J. Chem. Soc., pp. 2134-2136 (1970).
Doleschall et al.; Acta. Chemica Acadamiae Scientiarium Hungaricae, 45, pp. 357 368, (1965). *
Doleschall et al.; Acta. Chemica Acadamiae Scientiarium Hungaricae, 45, pp. 357-368, (1965).
Evans et al.; J. Exp. Med. 15: 727 731, (1972). *
Evans et al.; J. Exp. Med. 15: 727-731, (1972).
Fleming et al.; Circ. 50: Sup. III, 1148, (1974). *
Grout et al.; J. Chem. Soc., p. 3551, (1960). *
Hardtmann; Chem. Abstr., 74, 42373g (1971). *
Jen et al.; J. Med. Chem., 15, pp. 727 731, (1972). *
Jen et al.; J. Med. Chem., 15, pp. 727-731, (1972).
Lempert et al.; Experientia, 18, 401, (1962). *
Loev et al.; Experientia, 27, p. 875, (1971). *
Mustard et al.; J. Lab. and Clin. Med., 64: 548 559, (1964). *
Mustard et al.; J. Lab. and Clin. Med., 64: 548-559, (1964).
North et al.; J. Het. Chem., pp. 655 662, (1969). *
North et al.; J. Het. Chem., pp. 655-662, (1969).
Robinson, Ann. Rep. Med. Chem.; Ch. 6, pp. 49 53 (1969). *
Robinson, Ann. Rep. Med. Chem.; Ch. 6, pp. 49-53 (1969).
Simonov et al.; Pharm. Chem. Jour., pp. 4 6, (1969). *
Simonov et al.; Pharm. Chem. Jour., pp. 4-6, (1969).

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690925A (en) 1984-02-15 1987-09-01 Syntex (U.S.A.) Inc. (2-Oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl) oxyalkylamides properties having phosphodiosterase inhibiting
US4837239A (en) 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US4670434A (en) 1985-11-14 1987-06-02 Syntex (U.S.A.) Inc. (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors
US5801245A (en) * 1995-12-04 1998-09-01 Roberts Laboratories Inc. Process for the preparation of ethyl-N-(2,3 dichloro-6-nitrobenzyl) glycine
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6306889B1 (en) 1997-09-03 2001-10-23 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6380211B1 (en) 1997-09-03 2002-04-30 Guilford Pharmaceutical Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US7307080B2 (en) 1999-09-01 2007-12-11 Mgi Gp, Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US20050074470A1 (en) * 1999-09-01 2005-04-07 Guilford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6716828B1 (en) 1999-09-01 2004-04-06 Guilford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6376242B1 (en) 1999-09-21 2002-04-23 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
US6585995B1 (en) 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
US20040087486A1 (en) * 1999-09-21 2004-05-06 Hanson Stephen R. Methods and compositions for treating platelet-related disorders
US20040087035A1 (en) * 1999-09-21 2004-05-06 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
US7022521B2 (en) 1999-09-21 2006-04-04 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
US6194420B1 (en) 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
US6348475B1 (en) 2000-06-01 2002-02-19 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
US6545011B2 (en) 2000-07-13 2003-04-08 Guilford Pharmaceuticals Inc. Substituted 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones, derivatives thereof and their uses
EP1700841A2 (en) 2000-07-26 2006-09-13 Shire US Inc. Method for the Manufacture of Anagrelide
EP1700859A2 (en) 2000-07-26 2006-09-13 Shire US Inc. Method for the manufacture of anagrelide
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
EP1700840A2 (en) 2000-07-26 2006-09-13 Shire US Inc. Method for the Manufacture of Anagrelide
EP1700842A2 (en) 2000-07-26 2006-09-13 Shire US Inc. Method for the Manufacture of Anagrelide
EP1700843A2 (en) 2000-07-26 2006-09-13 Shire US Inc. Method for the Manufacture of Anagrelide
US6653500B2 (en) 2000-07-26 2003-11-25 Shire Us Inc. Method for the manufacture of Anagrelide
US20040209907A1 (en) * 2003-01-23 2004-10-21 Richard Franklin Formulation and methods for the treatment of thrombocythemia
US7700608B2 (en) 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060052601A1 (en) * 2004-08-04 2006-03-09 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US20100093772A1 (en) * 2004-08-04 2010-04-15 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2377530A2 (en) 2005-10-21 2011-10-19 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2382975A2 (en) 2006-05-09 2011-11-02 Braincells, Inc. Neurogenesis by modulating angiotensin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100137343A1 (en) * 2006-11-28 2010-06-03 Shire Llc Substituted quinazolines
US7910597B2 (en) 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
US20080176875A1 (en) * 2006-11-28 2008-07-24 Shire Llc Substituted quinazolines
US20080176877A1 (en) * 2006-11-28 2008-07-24 Shire Llc Substituted quinazolines
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US20100305318A1 (en) * 2007-12-19 2010-12-02 Watson Pharma Private Limited Process for the Manufacture of Anagrelide Hydrochloride Monohydrate
US20110071174A1 (en) * 2008-05-16 2011-03-24 Shire Llc Substituted quinazolines
US20110071172A1 (en) * 2008-05-16 2011-03-24 Shire Llc Substituted quinazolines as blood platelet lowering agents
US20110071173A1 (en) * 2008-05-16 2011-03-24 Shire Llc Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases
WO2009138795A1 (en) 2008-05-16 2009-11-19 Shire Llc Substituted quinazolines
US9040483B2 (en) 2008-06-16 2015-05-26 Biovascular, Inc. Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US9381198B2 (en) 2008-06-16 2016-07-05 Biovascular, Inc. Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US20090324710A1 (en) * 2008-06-16 2009-12-31 Glidden Paul F Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110112236A1 (en) * 2009-11-12 2011-05-12 Kraton Polymers U.S. Llc Thermoplastic polyurethane block copolymer compositions
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2011114160A1 (en) 2010-03-18 2011-09-22 Shire Llc Anagrelide derivatives (imidazo [2, 1-b] quinazolin - 2 - ones ) as pde iii inhibitors useful as antithrombotic agents
WO2012052781A1 (en) 2010-10-21 2012-04-26 Shire, Llc Process for the preparation of anagrelide and analogues thereof
US9067944B2 (en) 2010-10-21 2015-06-30 Shire Llc Process for the preparation of anagrelide and analogues thereof
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof

Similar Documents

Publication Publication Date Title
USRE31617E (en) Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3932407A (en) Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
FI77455B (en) PROCEDURE FOR FRAMSTATION OF ANTIHYPERTENSIVE 2,4-DIAMINOKINAZOLINEFOERENINGAR.
US3983120A (en) Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
Mandour et al. Synthesis, anti-inflammatory, analgesic and anticonvulsant activities of 1, 8-dihydro-1-aryl-8-alkyl pyrazolo (3, 4-b) indoles
US3988340A (en) 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
JPH03181469A (en) Quinazolin-3-alkanoic acid derivative, salt and production thereof
CA1055024A (en) Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo (2,1-b)quinazolin-2-ones
JPH0471914B2 (en)
US4950670A (en) 6-phenyl-3-(piperazinyalalkyl)-2,4(1H,3H)-pyrimidinedione derivatives, their preparation and their application in therapy
ISHIKAWA et al. Cyclic guanidines. IX. Synthesis of 2-amino-3, 4-dihydroquinazolines as blood platelet aggregation inhibitors
Chen et al. Synthesis of 7‐phenylpyrimido [5, 4‐d][1] benzazepin‐2‐ones
JPH04273878A (en) Heterocyclic compound and preparation thereof
Aly Synthesis and antimicrobial activity of some annelated quinazoline derivatives
NO873108L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,4-BENZODIAZEPINES.
US4202895A (en) 1-Polyhaloalkyl-2(1H)-quinazolinone derivatives
SU1169538A3 (en) Method of obtaining tricyclic compounds
CS114291A3 (en) Benzothieno-[2,3-b] pyrazine-2,3-(1h,4h) diones, processes for their preparation and a pharmaceutical comprising them
US4053600A (en) Tricyclic 1,2,4-triazolo-quinazolines
US4745115A (en) Isoquinolines or benzisoquinoliner having antiinflammatory activity
US3764600A (en) 1-substituted-quinazoline-2(1h)-thiones
US4372956A (en) 5, 10-Dihydroimidazo[2,1-b]quinazolines and pharmaceutical compositions containing them
Loriga et al. Quinoxaline chemistry Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10-propargyl-5, 8-dideazafolic acid (CB 3717) and its precursors. Synthesis and evaluation of in vitro anticancer activity
Rosowsky et al. Synthesis of 2, 4‐diamino‐9H‐indeno [2, 1‐d] pyrimidines
Said et al. Pharmacological activities of some synthesized substituted pyrazole, oxazole and triazolopyrimidine derivatives

Legal Events

Date Code Title Description
CC Certificate of correction